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Abstract 
Background: Patients with autoimmune disease have increased incidence of stroke. Hemorrhagic 
stroke (HS) is associated with loss of cerebrovascular function, leading to micro-vessel burst, 
and hemorrhage. We believe chronic inflammation is involved in loss of cerebrovascular 
function and HS. We established a hypertensive-arthritis model in spontaneously hypertensive 
rats (SHR) fed either standard rodent diet (0.59% NaCl) (RD) or high salt diet (4% NaCl) (HSD) 
and compared them to non-inflamed SHR. Methods: Complete Freund’s adjuvant (CFA) was 
injected into the left paw to induce mono-arthritis. Blood pressure and inflammation was 
monitored. At endpoint, animals were sacrificed and evaluated for HS while middle cerebral 
artery (MCA) was isolated for functional studies. Results: HS was observed in 90% of CFA-
treated groups. The MCA of arthritic RD-SHR exhibited decreased ability to undergo pressure 
dependent constriction (PDC). All HSD-SHR showed a decreased response to PDC. However, 
arthritic HSD-SHR also demonstrated a diminished response to vasoactive peptides. Conclusion: 
HS occurring with CFA injection corresponds with loss of MCA function. Chronic HSD appears 
to further exacerbate vascular dysfunction in the MCA. 
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1.0: Introduction and Statement of Problem 
Arthritis is a long term, physically debilitating disease that is the second most common 
chronic condition in Canada, with an annual cost of $33 billion in related health care costs (1). 
Rheumatoid arthritis (RA) is one of the more severe forms of arthritis. As a chronically 
progressive inflammatory disease, it can attack one or more joints, leading to joint degradation 
and loss of mobility. In addition to the destruction of joints and cartilage, the pathology of 
arthritic disease takes a progressive toll on many other tissues in the body as it produces diffuse 
inflammation in the lungs, pleura, pericardium, and sclera (2). The leading cause of death in RA 
patients is not due to the arthritis itself however, but due to cardiovascular (CV) complications, 
leading to a 3-fold increase in associated mortality compared to the general population (3-5). 
The risk of ischemic heart disease and myocardial infarction has been extensively studied 
in RA, but more recent and fundamental studies indicate significant risk of stroke in autoimmune 
arthritis, with patients with RA having a 30% increase in stroke over age-matched controls (6, 7).  
Of all stroke subtypes, hemorrhagic stroke (HS) has the highest mortality rate, approaching 50% 
within the first month (8, 9). The risk of death from the first incidence of stroke has also been 
shown to be significantly higher for RA patients compared to non-arthritic subjects (3, 10, 11). 
Evidence suggests that traditional risk factors of cardiovascular disease (CVD), (hypertension , 
smoking, dyslipidemia,  and insulin resistance) are more prevalent in the RA population (12). 
There is also an increased risk of myocardial infarction, CV morbidity, and CV mortality in RA 
patients (13).  The evidence in the literature suggests that approximately two-thirds of patients 
with primary cerebral hemorrhage have pre-existing or newly diagnosed hypertension (8, 14). 
The presence of hypertension, either salt-sensitive or not, is in itself a key risk factor for HS and 
may therefore be a key component in the likelihood of RA patients developing fatal HS.  
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Animal models have been used for decades to study the pathogenesis of arthritis akin to 
RA (the adjuvant induced arthritis rats; AIA rats) (15-17). Similarly, the stroke-prone 
spontaneously hypertensive rat (SHRsp) is widely used to study HS (18). However, there is 
currently no model that exemplifies the chronic development of HS subsequent to chronic 
systemic inflammation induced by mono-arthritis and longstanding hypertension. Although, 
chronic hypertension and chronic inflammation have both been independently linked to various 
degrees of vascular dysfunction (19-21), the impact of both of these factors together on vascular 
function has not yet been investigated. In particular, functional studies of the MCA in a 
chronically inflamed spontaneously hypertensive rat (SHR), has not yet been studied.   
Autoregulation of cerebral blood flow is governed by a variety of physical cues 
(including sheer stress and pressure) and endogenous chemical stimuli (such as peptides, 
nucleotides and cytokines)(22, 23). Pressure dependent constriction (PDC) is one such 
mechanism by which the cerebral vasculature ensures adequate and controlled perfusion of the 
small arteries feeding the brain (24). As perfusion pressures increase, the blood vessel reflexively 
constricts to prevent over-perfusion of the downstream vasculature and maintains a constant 
flow. Studies in pre- and post-stroke SHRsp have revealed that after hemorrhagic stroke has 
occurred, the PDC mechanism is lost in the middle cerebral artery (MCA) along with signs of 
renal failure (18).  
Cytokines and growth factors are able to genetically alter the functioning of the vascular 
endothelium, directly affecting the expression of various activators of endothelial function over a 
sustained period. This can potentially lead to the modulation of local second messengers such as 
changes in intracellular Ca2+ concentrations and cyclic nucleotides (23). As a result, vascular 
functioning becomes altered. Kessler et al showed that proinflammatory cytokines (interleukin-
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1β, and tumor necrosis factor-a (TNF-α)) and lipopolysaccharide decreased endothelial-mediated 
vascular relaxation through decreased production of endothelial derived hyperpolarizing factor 
(EDHF). Interestingly, this coincided with increased expression of nitric oxide synthase (NOS), 
resulting in increased nitric oxide (NO) production (25). In this way, the surge of circulating pro-
inflammatory cytokines can possibly have a profound impact on the cerebral vascular 
functioning, leading to vasoconstriction or vasodilation. 
Our objective was to address this gap in knowledge by creating a hypertensive-arthritic 
animal model with the induction of adjuvant mono-arthritis in the stroke-resistant SHR, a strain 
unique in that it normally develops spontaneous hypertension but does not spontaneously 
develop stroke. We planned to determine whether induction of monoarthritis increases the 
propensity for HS in the SHR strain. We also chose to investigate the impact of high salt diet 
(4% NaCl) on the severity of systemic inflammation and HS. We further examined the impact of 
chronic inflammation and concurrent hypertension on the ability of the MCA to perform PDC 
and its responsiveness to vasoactive peptides (bradykinin, vasopressin), NOS inhibition (Nω-
nitro-L-arginine methyl-ester; L-NAME) and protein kinase C (PKC) activation (phorbol 
dibutyrate) in order to elucidate underlying mechanisms of vascular dysfunction in the 
hypertensive arthritic rat model.  
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2.0: Review of Literature 
2.1: Inflammatory Arthritis 
In Canada, more than 4.6 million people have reported that they suffer from one or more 
of the various types of arthritis. Although two-thirds of the people who are affected are women, 
it is the third most common cause of disability in the country among men (26). Inflammatory 
arthritis is recognized by the surge in migration of immune cells including 
monocytes/macrophages, lymphocytes and granulocytes to the synovial lining of the affected 
joint (27). Enhanced proliferation of synovial fibroblasts at the affected joint(s) also sustains the 
inflammatory process and helps to initiate and perpetuate joint degeneration (27, 28). This 
process translates to pain, redness and swelling of the joint(s) which then eventually results in 
decreased mobility and joint degradation (29). In spite of the fact that the joint inflammation is 
often fully reversible, the resulting damage and degeneration of the joint is not, making 
inflammatory arthritis a chronically progressive degenerative disease (29-31). While 115-271 in 
every 100,000 people are diagnosed with inflammatory arthritis each year, 70% of these go on to 
receive a diagnosis of Rheumatoid Arthritis (32).  
2.1.1: Rheumatoid Arthritis: Clinical Definition and Prevalence 
Rheumatoid Arthritis (RA) affects approximately 300,000 Canadians with a frequency of 
about 1 in 100 people (26). Women are more than twice as likely as men to develop RA, and 
around 30% of patients will stop working within two years after the onset of disease, mainly due 
to the physically debilitating and rapidly progressing effects of this condition (33). This leads to 
a large economic impact due to costs to the healthcare system as well as lost productivity. RA 
can present at any age, but the majority of patients will present between the ages of 40-60 (26). 
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RA is most commonly recognized as being a chronic, symmetrical inflammatory 
condition of the joints that can also affect various other organ systems over time (2). It is 
characterized by three main changes within the affected joints; inflammation and proliferation of 
the synovial tissue (ie; pannus formation), thinning of the articular cartilage, and subsequent 
focal erosion of the subchondral bone (34). It is the pannus, a highly proliferative cellular 
membrane of granulation-reactive fibrovascular tissue, that extends into the articular cartilage of 
the joint and proceeds to break down the bone. Subsequent structural damage to the joint itself is 
carried out by osteoclasts, multinucleated giant cells that are specially designed to degrade the 
mineralized components of the cartilage and underlying bone, where they localize to the pannus-
bone interface (34). The inflammatory infiltrate of the pannus is comprised of six main types of 
immune cells; namely T cells, B cells, plasma cells, dendritic cells, mast cells and granulocytes 
(34). Precipitating factors that trigger this dysfunctional burst of inflammatory activity 
synchronized with diminished self-tolerance are widely unknown. However, genetics, 
environmental factors such as cigarette smoking and immunologic factors are assumed to play a 
role (26). 
As such, RA still presents as a highly heterogenous disease with largely unknown 
etiology. Diagnosis is made based on a number of criteria evaluating the number of joints 
affected (with at least one joint showing signs of clinical synovitis which can not be explained by 
other causes), and the presence or absence of certain serological markers such as Rheumatoid 
Factor (RF) and Anti-Citrullinated Protein Antibody (ACPA) (35). The duration of symptoms 
(being greater than six weeks) and elevations in circulating acute phase reactants such as C-
reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR) (35) are also used as 
indicators of severity of the disease. It is classified as an autoimmune disease due to the presence 
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of RF, which serves as an autoantibody to the Fc fragment of immunoglobulin G (IgG). 
However, research shows that increased ACPA activity is more relevant to the autoimmune 
disease process than RF (36). Citrullination, the enzymatic conversion of the amino acid arginine 
to citrulline, is a critical step in development of autoimmunity as this leads to the recognition of 
several highly expressed proteins of the synovium (fibronectin, collagen type II, vimentin, fibrin) 
by ACPA during the inflammatory process (37). Therefore the disease development can be 
characterized in three separate phases starting with immune sensitization, proceeding to an 
inflammatory response which ends in bone and joint erosion (37). In some cases, the initial phase 
(lymphoid/pre-articular phase) of disease development may present 10-15 years before clinical 
signs and symptoms of RA become apparent (36, 38). 
2.1.2: Pathophysiology of Rheumatoid Arthritis 
Predisposition to the development of RA has been linked to several genetic susceptibility 
loci (such as HLADRB1 (Human Leukocyte Antigen class II antigen DRβ1), PTPN22 (protein 
tyrosine phosphatase, non-receptor type 22) and CTLA4 (cytotoxic T lymphocyte antigen 4), 
some of which are immune-regulated (39). Environmental factors that have been correlated to 
increased risk of RA development are cigarette smoking (40), caffeine consumption, and obesity 
(41) while a Mediterranean Diet and diets rich in antioxidants seem to have protective effects 
(42). Circulating levels of RF and/or ACPA have been shown to be increased for several years 
prior to the development of symptoms, leading to increased levels of acute phase reactants and 
inflammatory mediators such as cytokines and chemokines. While the final culmination of 
events that leads to arthritic symptoms are largely unknown, retrospective studies have identified 
infection, trauma and stress to be triggers prior to clinical manifestation (38).  
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Following immune activation, the innate and acquired immune systems work 
concurrently to perpetuate the inflammatory process. Dendritic cells in the joint become 
activated by exogenous and autologous antigens while antigen presenting cells (APC’s) 
(including dendritic cells, macrophages and activated B cells) start binding to arthritis-associated 
antigens (43, 44). Meanwhile, CD+ T cells located in the synovium begin secreting IL-2 and 
IFN-γ locally. Once activation of B-cells and T-cells has occurred, a large amount of 
inflammatory cytokines (such as IL-12, 15, 18 and 23) (37) and CC and CXC chemokines are 
produced which further feeds back into the cycle to increase T-cell, B-cell and macrophage 
activation. The increased activation further drives the inflammatory response by production of 
IFN-γ, IL-2, 12, 18 and granulocyte macrophage-colony stimulating factor (43, 44). Another 
important function of activated macrophages and dendritic cells is to provide the necessary 
inflammatory setting to trigger activation of the Th17 pathway. This is initiated by a surge in 
production of TGF-β, IL-1β, 6, 21 and 23 which together cause a shift in T-cell homeostasis to 
diminish production of regulatory T-cells (Tregs) and increase differentiation of the Th17 
subtype, shifting the balance towards an inflammatory milieu (37). 
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Figure 2.1: Pathogenesis of Bone Destruction in Rheumatoid Arthritis. In RA, the synovium of 
the joint becomes inflamed and begins to destroy the underlying bone. Bone destruction is 
mediated by osteoclasts. Increased levels of RANKL in the synovium causes the induction of 
osteoclasts. Th17-cell infiltration into the joint produces IL-17 which activates synovial 
macrophages to produce several other pro-inflammatory cytokines such as TNF-α, IL-1 and IL-
6, which also increase proliferation of osteoclasts. IL-17 also triggers the activation of synovial 
fibroblasts which further increases expression of RANKL, further perpetuating bone 
degeneration. 
Adapted from Takayanagi, 2007. 
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Figure 2.1: Pathogenesis of Bone Destruction in Rheumatoid Arthritis 
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In RA, the Th17 pathway is responsible for the production of IL-17A, -17F, -21 and -22 
as well as TNF-α to perpetuate the inflammatory process and exacerbate bone erosion and joint 
degeneration (45, 46). The IL-17 receptor (IL-17R) is widely expressed on many of the immune 
cells involved in RA pathology including fibroblasts, endothelial cells, epithelial cells and 
neutrophils, lending evidence to the ubiquitous role of this cytokine in the inflammatory disease 
process (47). IL-17A acts synergistically with TNF-α to further activate synovial fibroblasts, 
chondrocytes and osteoblasts and suppress differentiation of Tregs (46, 48). Aside from the 
diffuse production of pro-inflammatory mediators, the Th17 pathway is critical in joint 
degeneration. IL-17 produced in the synovium serves to activate receptor activator of nuclear 
factor kappa B ligand (RANKL) signaling in multiple ways. RANKL activity is important 
because it is the main mechanism by which osteoclast progenitor cells become activated to 
produce osteoclasts, which actively mediate bone destruction (37, 48). Although Th17 cells 
express RANKL on their cellular membrane, the main mechanism by which signaling through 
this ligand is initiated is through the actions of activated synovial fibroblasts. IL-1, -6 and -17, as 
well as the actions of TNF-α (among other pro-inflammatory cytokines) are able to directly 
induce RANKL signaling to cause joint damage although IL-1, -6 and TNF-α are also able to 
activate osteoclast progenitor cells independent of RANKL signaling (37). These pro-
inflammatory cytokines also promote the continuing differentiation of B-cells and cause release 
of several different matrix metalloproteases (primarily MMP-1, -3, -8, -13, -14 and -16) (37) 
which can also activate osteoclasts but serve to degrade the cartilage in the inflamed joints (49). 
As Th-17 cells do not synthesize IFN-γ, a suppressor of RANKL signaling, bone metabolism and 
osteoclastogenesis is further enhanced (50) (Figure 2.1). 
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2.1.3: Animal Models of Rheumatoid Arthritis 
Animal models are widely used in the investigation of multiple types of arthritis. They 
are an invaluable tool in the study of the pathogenesis of various aspects of arthritic disease but 
are also commonly used to test treatments for these same conditions. Rodent models of arthritis 
have two main limitations; 1) rodent arthritic process progresses more rapidly than human 
arthritic disease necessitating caution when interpreting results of acute pathological changes as 
opposed to chronic changes and 2) joint inflammation in rodents is often characterized by bone 
resorption and formation, which is not consistent with human inflammatory arthritic disease, as it 
is characterized by bone erosion only (51). The most common types of RA animal models 
include adjuvant arthritis (AA), rat type II collagen arthritis and antigen arthritis (51). 
Adjuvant arthritis is one of the most common experimental modalities for studying RA 
disease progression and experimental treatments. Adjuvant injection results in a reproducibly 
rapid and robust, polyarthritic immune response with mild cartilage erosion and significant bone 
resorption (51-53). Although the exact mechanism of pathological response has not been fully 
elucidated, data suggests that the immune response may involve reactivity to proteoglycans 
produced in cartilage, heatshock proteins or even the rodent’s intestinal bacterial flora (54-56). 
The most commonly used rat strain in adjuvant arthritis is the male Lewis rat. Female Lewis rats 
are also commonly used, however they produce a more variable disease progression (57). Male 
Sprague Dawley and Wistar rats are also frequently used in this model (58). Arthritis induction is 
initiated by either tail-base or footpad injection of Complete Freunds Adjuvant (CFA) containing 
mycobacterium suspended in an oily vehicle or a synthetic compound, N,N-dioctadecyl-N',N'-
bis(2-hydroxyethyl) propanediamine, suspended in mineral oil or olive oil (59). Adjuvant 
activity is a result of sustained release of antigen from the oily deposit and stimulation of a local 
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innate immune response resulting in enhanced adaptive immunity. Footpad injection may be 
preferred to tail-base injection as it represents a moderate arthritic response, compared to the 
more severe inflammatory response produced by tail-base injection (60). Additionally, it allows 
monitoring of the initial acute local inflammatory response as well as the tracking of arthritic 
changes as the inflammation transitions to a chronic, systemic inflammatory response (51). 
Monitoring of inflammatory changes to the hind paw are typically conducted every second day 
starting at baseline by caliper measurements at the ankle joint, and/or water volume displacement 
measurement of the entire paw. Signs of clinical, systemic disease are usually apparent by Day 9 
of the experimental protocol (51). 
Rat collagen-induced arthritis (CIA) is commonly induced by footpad or tail-base 
injection with homologous or heterologous type II collagen emulsified in incomplete Freunds 
adjuvant (IFA), producing an inflammatory process that mimics the joint degradation present in 
human RA more closely than adjuvant arthritis. Polyarthritis progression is characterized by 
diffuse cartilage degeneration, localization and deposition of immune complexes at the joint 
surface, moderate to severe synovitis and osteodegeneration (51, 61, 62). In this model, females 
tend to be more susceptible to arthritis development (as in human RA) with a severe-erosive 
poly-arthritic syndrome developing 14-21 days post-injection due to the self-sensitization to 
articular collagen (61, 63). As such, articular cartilage degeneration is the primary target of the 
disease process, with significant bone damage but minimal loss in paw volume (64).  
CIA differs from AA in that the immunogenic response is primarily mediated by B-cell 
activation to a greater extent than adjuvant arthritis (61). Also, the more extensive pannus 
formation at the articular sites correlates better to human RA as well. In spite of this, the AA 
method has been favored in the past due to the wealth of data that already exists with this model 
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(51). Regarding arthritis induction protocols, the AA model frequently only involves a single 
injection while CIA requires a booster injection on the seventh day of the experimental timeline 
(64). In spite of this, AA exhibits an earlier onset and more rapid plateau of inflammation than 
CIA, which may take up to 21 days to see a maximal inflammatory response (64). Although 
polyarthritis is evident in both models, only the inflammation in the injected paw is relevant in 
the AA model whereas inflammation of both ankles and knees of CIA rats are considered 
significant (64). This may cause undue discomfort and stress to the rats, from an animal welfare 
point of view, especially since both models produce similar pathology scores (64). Both CIA and 
AA rats have shown to have similar levels of circulating (serum) pro-inflammatory mediators 
(such as IL-1β, TNF-α, IL-6, iNOS and MMP-13) however mRNA for cytokine levels in the 
joint are significantly elevated in the AA model compared to CIA (64). Additionally, total 
neutrophil counts are 5-7-fold higher in AA rats (compared to control) whereas the CIA model 
produces a more modest increase in neutrophils at 3-4 times that of control (64). Therefore, both 
methods are commonly used, but there are several distinct differences between the AA and CIA 
models.      
Antigen arthritis is a mechanism of arthritis induction that is amenable to virtually any 
animal model. It involves the subcutaneous or intradermal injection of a positively charged 
antigen that binds to negatively charged cartilage and remains present in the joint. Most 
commonly the cationic antigen used is methylated-bovine serum albumin (m-BSA), which after 
binding to the cartilage, elicits binding of antibody complexes which then causes compliment 
activation and local cartilage degeneration (51, 57). This model is commonly used in various 
mouse strains (65) but also in rats (66),  guinea pigs (67) and rabbits (68). Some protocols 
require habitual injection at weekly or twice-weekly intervals as well as combination of m-BSA 
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with CFA for injection directly into the selected joint. By the end of two weeks, severe cartilage 
destruction has already occurred due to pannus formation (51). 
2.2: Rheumatoid Arthritis and Cardiovascular Disease 
One of the leading causes of death among individuals with RA is due to cardiovascular 
disease (69). RA patients have an increased risk of myocardial infarction (MI), heart failure, 
stroke and peripheral vascular disease (69-72). Although non-steroidal anti-inflammatory drug 
(NSAID) use in the RA population has been associated with significant cardiovascular toxicity 
and associated MI risk (73), it is becoming more commonly accepted that increased CV 
morbidity and mortality rates in this population are likely not completely attributable to RA 
treatments (73, 74). After controlling for other modifiable and non-modifiable traditional risk 
factors such as increased body mass index, diabetes, smoking, diet and gender, multiple large-
scale trials still showed an increased risk for CV events in the RA population that was not 
otherwise explained (75-78). This suggests that there is an increased risk of CV disease 
conferred by the presence of RA itself. It has been proposed that the actions of high levels of 
circulating pro-inflammatory cytokines linked to RA pathogenesis (IL-6 and TNF-α) may be 
partially responsible for this increased risk. IL-6 is involved in increasing levels of acute phase 
reactants and is blamed, along with TNF-α, for altering the composition of circulating lipid 
particles contributing to dyslipidemia and atherosclerotic plaque destabilization (37, 79).   
2.2.1: Rheumatoid Arthritis and Hypertension 
A recent study examined CV risk factors present in a group of 73 RA patients and found 
that hypertension was present in more than 50% of these individuals (80). Another observational 
study from the United Kingdom, showed hypertension (defined as systolic blood pressure of ≥ 
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140 mmHg and/or diastolic blood pressure of ≥ 90 mmHg) was identified in 70.5% of the 400 
RA participants. Of those identified as being hypertensive, only 60.6% were treated with anti-
hypertensive medications and only 21.8% of those treated were meeting their blood pressure 
target (81). Lack of appropriate blood pressure control was attributed to both poor medication 
adherence and a lack of anti-hypertensive therapy optimization (such as, sub-therapeutic dosing 
or inappropriate drug selection). This demonstrates the high level of prevalence of hypertension 
among the RA population. Although many other investigators have confirmed that hypertension 
is highly prevalent in RA (82-84), the incidence of hypertension compared to the general 
population is also greater in RA (84). Proposed mechanisms of this increased risk include 
increased arterial stiffness (85), anti-rheumatic drug therapy (including NSAIDs, corticosteroids 
and some disease-modifying anti-rheumatic drugs) and abnormal vascular function characterized 
by decreased elasticity in small and large arteries associated with increased vascular resistance 
(86). 
2.2.2: Rheumatoid Arthritis and Stroke 
Multiple epidemiological studies have shown that risks for cerebrovascular accidents 
(CVA) are also increased in RA patients (77, 87). This data can be partially explained by the 
high prevalence of hypertension in RA populations, which is the most important modifiable 
cerebrovascular risk factor for stroke development (88). RA has also recently been identified as 
an independent risk factor for accelerated atherosclerosis, which is a major risk factor for 
ischemic stroke (77, 89, 90). Along with increased risk of stroke, there is a 50% greater chance 
of case fatality associated with stroke development in the RA cohort (89). Although 
approximately 80% of stroke are of the ischemic subtype and strongly linked to atherosclerotic 
pathology, around 20% of stroke are hemorrhagic which are characterized by cerebral vessel 
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burst and high mortality (91). The etiology of hemorrhagic stroke is largely unknown, especially 
in the setting of RA.  
2.2.3: Interleukin-17 and Cardiovascular Disease 
   While the link between cardiovascular disease and endothelial dysfunction and 
inflammation has already been well established, the exact role of individual circulating cytokines 
in CV disease remains largely unknown (92, 93). Reports have indicated that high circulating 
levels of TNF-α and IL-6, as seen in RA, are associated with the progression in cardiovascular 
damage after controlling for traditional cardiovascular risk factors (19, 94). However, it is 
unclear whether these cytokines play a role in the development of primary vascular dysfunction. 
Recently, the role of IL-17 in RA progression as well as CV disorders has received much 
attention (95-97). In non-RA animal models, IL-17 has been associated with accelerated 
myocardial fibrosis, atherosclerosis, endothelial dysfunction and increased superoxide formation 
(97-99). It has been observed that IL-17 may induce the phosphorylation of Thr495 of eNOS at 
its inhibitory site, causing a conformational change in the enzyme which interferes with 
calmodulin binding and diminishes enzyme activity (100, 101). This is one proposed mechanism 
by which IL-17 may play a role in endothelial dysfunction. However, more information is 
needed regarding the direct vascular effects of IL-17.  
2.3: Dietary Sodium and Cardiovascular Disease  
The deleterious effect of high dietary sodium intake on the cardiovascular system has 
been widely accepted (102, 103). In salt-sensitive individuals, it plays a role in hypertension 
development (102, 104) through several mechanisms including extracellular volume increase, 
increased cardiac output (105), activation of the sympathetic nervous system (104) and impaired 
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hormonal responses through the renin-angiotensin-aldosterone system (106, 107). However, in 
normotensive individuals high salt diets can also cause target organ damage to the heart, kidneys, 
arteries and the rostral ventral lateral medulla (RVLM - the area of the brain that mediates 
sympathetic outflow to regulate blood pressure) (108). High salt intake is correlated to increased 
left ventricular wall thickness and mass, regardless of whether the patient is hypertensive or 
normotensive (109) and reduced renal function (110). Studies using rodents have shown that 
high salt diet can increase the sensitivity of excitatory neurons in the RVLM, increasing 
sympathetic response to various stimuli (111), including exercise (112). This leads to greater 
variability in blood pressure, which is also a risk factor for target organ damage and CV events 
(113, 114).  
Increased vascular and arterial stiffness is another predictor of CV events which has been 
correlated to a high sodium diet (115). Vascular stiffening is the result of vascular remodeling 
that becomes augmented in the presence of various external stimuli, including a high sodium 
diet, certain comorbidities such as hypertension and dyslipidemia, and the normal aging process 
(115, 116). This remodeling is characterized by vascular hypertrophy (inward remodeling) and 
altered composition of the VECM leading to more collagen deposition and decreased presence of 
elastin (117, 118). This results in decreased vascular compliance and vascular dysfunction.     
There are several mechanisms by which increased sodium intake is proposed to cause 
generalized vascular dysfunction. Numerous studies using rodents, possibly including our own, 
have linked endothelial dysfunction to elevated dietary sodium (119-122), irrespective of blood 
pressure. Increased generation of ROS (including superoxide) leading to diminished NO 
bioavailability are the most commonly proposed mechanisms (119-122). In addition, studies 
using cell culture techniques have also demonstrated that small increases in intracellular sodium 
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concentrations can alter the fundamental mechanics of the endothelial cell, causing stiffening of 
the endothelial cortex, by changing the cell’s transcriptome (123-125). This leads to decreased 
NO production, and altered barrier functions, resulting in increased flux of plasma across the 
microvascular endothelial barrier (126). This process is thought to be fed by the endothelial 
sodium channel (EnNaC) which is involved in a “feed-forward” loop with extracellular Na+ 
concentration. In the setting of high extracellular Na+ concentrations, the EnNaC becomes more 
abundantly expressed on the cell surface, thus allowing increased Na+ influx into the cell (127). 
This in turn increases intracellular Na+ levels which stabilizes the interaction between certain 
cortical cytoskeletal proteins (actins) leading to the stiffening of the cell (128). In this way, 
increased plasma Na+ concentrations are able to have damaging effects on the vasculature of 
individuals, regardless of their level of salt sensitivity or salt resistance.    
2.4: Cerebral Vascular Function 
Due to the critical functions of the brain and fragility of cerebral blood vessels, blood 
flow must be tightly regulated. In humans, the brain requires 15% of cardiac output and 25% of 
total body glucose in order to maintain day-to-day functions. In addition, the brain receives 
nearly one fifth of total body oxygen, extracting about 50% of the oxygen carried in arterial 
blood (129). This large blood flow requirement is proportional to the constant amount of oxygen 
and glucose required for brain mitochondrial cells to carry out oxidative phosphorylation to 
produce adenosine triphosphate (ATP), generating the energy required to maintain normal brain 
function (130). There are a number of factors that directly affect cerebral circulation including 
metabolic and chemical (CO2 and O2) needs of the brain as well as pressure mediated 
autoregulatory functions (131). In the setting of high neuronal activity, the brain’s metabolic 
needs increase, leading to increased blood flow to the higher activity regions of the brain in a 
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process called functional hyperemia (132). Chemical influences such as hypocapnia (low CO2, 
leading to tissue alkalosis) caused by hyperventilation or hypoxia (low O2, leading to tissue 
acidosis) caused by respiratory depression can also lead to a decrease or increase in cerebral 
blood flow respectively, in order to maintain homeostasis (131). Finally, pressure-mediated 
autoregulation refers to the ability of the certain vascular beds (including the cerebral 
vasculature) to maintain constant blood flow to downstream arterioles in the setting of pressure 
variations. In the setting of low perfusion pressures, cerebral arteries will reflexively dilate and 
alternatively constrict in times of pressure surges (133). The evidence in the literature suggests 
that a combination of neuronal, astrocytic and vascular signaling patterns allow the brain to 
maintain hemodynamic stability and respond to the brain’s changing needs for nutrients and 
oxygen (134). However, the remainder of this section will focus solely on the cerebral vascular 
function as it pertains to pressure mediated blood flow autoregulation. 
2.4.1: Endothelial Function 
The vascular endothelium is a dynamic layer of cells that is crucial in the control of 
vascular tone. Originally, the critical significance of the vascular endothelium was somewhat 
serendipitously discovered by Furchgott and Zawadski, who noted that helical strips of rabbit 
thoracic aorta produced a graded contractile response to increasing concentrations of 
acetylcholine (ACh) (135). However, when using a ring preparation of the same thoracic aorta, 
they observed a rapid and potent vasodilatory response, realizing that when producing their 
helical strip of aorta, they had been accidentally rubbing off the endothelial layer. This led them 
to acknowledge the importance of the endothelium in vascular relaxation responses (135). The 
study also concluded that activation of muscarinic receptors on the endothelium by ACh 
triggered the release of a diffusible substance which caused smooth muscle relaxation. Later 
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work by Furchgott, Ignarro and Murad identified this diffusible substance as nitric oxide (NO), 
later earning them a Nobel Prize (136). Over time, the identification of several other endothelial-
derived mediators of vascular tone have been described, including various 
prostaglandins/prostanoids (prostacyclin and thromboxane A2 being the most commonly 
recognized), endothelial derived hyperpolarizing factor (EDHF), endothelin (a powerful 
vasoconstrictor) and reactive oxygen species (ROS) (137-141). However, to date, NO is the most 
well studied and prominent endothelial modulator of vascular tone (136). 
Nitric oxide is synthesized in the vascular endothelium as a derivative of L-arginine by 
the enzyme, Nitric Oxide Synthase (NOS). It is primarily responsible for maintaining 
vasodilation within blood vessels. However, it also prevents platelet and leukocyte adhesion, and 
may even play a role in the prevention of hyper-proliferation of smooth muscle cells (142). 
Within the body, there exists three main types of NOS; neuronal NOS (nNOS), inducible NOS 
(iNOS) and endothelial NOS (eNOS). Within the vasculature, eNOS is the most diffusely 
expressed NOS isoform and is constantly producing a baseline amount of NO. Enzymatic 
activity is positively regulated in a Ca2+-calmodulin-dependent manner by shear stress and by 
various receptor-bound agonists (143). Activation of protein kinase C (PKC) inhibits this Ca2+-
calmodulin-mediated activation of eNOS (144). In addition, certain cytokines are also able to 
diminish mRNA expression and enzymatic activity of eNOS as well modulate the production of 
various endothelial agonists (142).  
Stimuli including sheer stress, hypoxia, pressure, and numerous chemical mediators such 
as catecholamines, nucleotides (eg. adenosine, adenosine triphosphate), peptides (eg. bradykinin, 
vasopressin, endothelin), fatty acids, proteases (eg. thrombin, trypsin) growth factors and 
cytokines can directly activate the vascular endothelium to produce endothelial modulators that 
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may increase or decrease endothelial-mediated relaxation (23). Alternatively, cytokines and 
growth factors are also able to modulate the expression of some of the above mentioned 
chemical mediators. To activate NO release, some of these chemical agonists bind to their 
respective G-protein-linked receptors on the vascular endothelium. The downstream signaling 
pathway includes G-protein coupling to phospholipase C (PLC) which activates inositol 
trisphosphate (IP3) and diacylglycerol (DAG) leading to intracellular and extracellular Ca2+ 
mobilization and Ca2+ influx through nonselective cationic channels. This intracellular Ca2+ 
increase allows Ca2+-calmodulin binding, which is a critical step in the activation of eNOS and 
thus the production of NO (23).  
Production of NO by NOS enzymes requires nicotinamide adenine dinucleotide 
phosphate (NADPH) as an electron donor to convert L-arginine to Nω-hydroxyl-L-arginine. 
Further oxidation yields NO and L-citrulline. Cofactors required for this enzymatic conversion 
include tetrahydrobiopterin, flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), 
and heme (142). Due to the highly soluble nature of NO, it readily diffuses across the cell 
membranes and binds to soluble guanylate cyclase to catalyze the conversion of cyclic glutamyl-
monophosphate (cGMP) to glutamyl-5'-triphosphate (GTP), activating protein kinase G (PKG). 
PKG initiates the phosphorylation of a series of cellular targets which causes a decrease in 
[Ca2+]i which produces vasodilation (145). Alternatively, NO has also been shown to cause 
hyperpolarization of vascular smooth muscle through the direct activation of Ca2+-dependent K+-
channels (K+Ca), independent of cGMP (146).  
Another pathway of endothelial-dependent relaxation that does not lead to the release of 
intermediate factors such as EDHF, NO or PGI2 is through various cation channels expressed on 
the vascular endothelium, but can be found on the vascular smooth muscle as well (147). 
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Transient receptor potential (TRP) channels are a family of Ca2+ permeable ion channels that 
regulate [Ca2+]i and cell membrane potential (148). As such, activation of these channels leads to 
an increase in [Ca2+]i which can then trigger changes in vascular tone, permeability, and even 
remodeling (148). Activation of these channels occurs through both capacitative (decrease in 
[Ca2+]i stores) and non-capacitative (signaling mediators including DAG, and  5,6-
epoxyeicosatrienoic acid, independent of intracellular Ca2+ stores) mechanisms in endothelial 
cells increasing vasodilation (148). Alternatively, in certain TRP channels (TRPV4), 
mechanotransduction of activation signals can lead to vascular smooth muscle hyperpolarization 
and consequently vasodilation. This response is thought to be attributed to the stimulation of 
Ca2+-sensitive K+ channels in vascular smooth muscle, while the same signaling mechanism is 
thought to occur in the vascular endothelium as well (149) (Figure 2.2).   
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Figure 2.2: Schematic Diagram of Endothelial-Mediated Vasodilation: Endothelial receptor 
activation and/or sheer stress can cause the endothelium to generate several vasodilatory 
mediators including EDHF, NO and PGI2. Release of these mediators causes vascular smooth 
muscle relaxation. In addition, activation of TRP channels located on the vascular endothelium 
increases intracellular calcium which triggers the opening of various ion channels, causing 
vascular smooth muscle hyperpolarization, also resulting in a relaxation response.    
TRPV4 – Transient Receptor Potential Vallinoid 4 Channel, EDHF – Endothelial Derived 
Hyperpolarizing Factor, eNOS – endothelial nitric oxide synthase, NO – nitric oxide, PGI2 – 
Prostaglandin I2, GTP – Guanine triphosphate, cGMP – cyclic guanine monophosphate, cAMP – 
cyclic adenosine monophosphate, ATP – adenosine triphosphate 
Adapted from Félétou & Vanhoutte (2009) 
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2.4.2: Vascular Smooth Muscle Control 
Vascular tone within the vasculature is maintained through the cooperation between the 
vascular endothelium and the smooth muscle. Therefore within the brain, the primary purpose of 
vascular smooth muscle is to generate and maintain vasoconstriction or facilitate vasorelaxation 
with the end goal of controlling blood flow. The processes of vasoconstriction and vasodilation 
are primarily (although not entirely) controlled by the respective increases and decreases in 
intracellular Ca2+ concentrations (150). When [Ca2+]i increases, it binds to calmodulin. This 
complex then activates myosin light-chain kinase (MLCK) which then leads to the 
phosphorylation of Ser19 on myosin at the regulatory site. Actin can then activate myosin 
ATPase leading to muscle contraction (150). In the case of endothelial-mediated vasodilation, 
activated endothelial cells become hyperpolarized (according to the mechanism previously 
described in section 2.4.1), spreading the wave of hyperpolarization along the length of the 
vessel and into the vascular smooth muscle cells through myoendothelial gap junctions. The 
resulting current then causes a decrease in the number of open L-type Ca2+ channels which leads 
to a fall in intracellular Ca2+ concentrations (151).  This drop in [Ca2+]i deactivates MLCK, 
leading to dephosphorylation of myosin light-chain Ser19 by MLC phosphatase and deactivation 
of actin-myosin ATPase ending in smooth muscle relaxation (150). 
The stimulus for smooth muscle constriction is generally incited by receptor activation 
through G-protein linked pathways or mechanotrasduction of signals received based on vessel 
stretch and stress (ie: stretch-activated cation channels) (152). Receptor agonists include 
endogenously produced chemicals such as norepinephrine, epinephrine, angiotensin II, 
vasopressin and endothelin, among others (152). Therefore, ligand binding to cell-surface 
receptors causes the activation of phospholipase C (PLC) through Gq/11 which then catalyzes the 
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cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) into IP3 and DAG, who serve as second 
messengers. Subsequent binding of IP3 to the IP3-receptor (IP3R) on the sarcoplasmic reticulum 
(SR) causes expulsion of Ca2+ from the SR, increasing [Ca2+]i causing vascular constriction as 
described above. In addition, the DAG formed from this receptor-ligand interaction also plays a 
role in vasoconstriction. PKC, which requires Ca2+ and DAG for activation, has several 
downstream effects. It is known to interact with MLCK, ERK1/2, Rho kinase and calmodulin-
dependent protein kinase II in addition to membrane channels to elicit vascular smooth muscle 
contraction (152, 153).  
When vascular smooth muscle receptor agonists (vasoconstrictors) bind to receptors, the 
final result is intracellular calcium release leading to muscle contraction, as described above. 
This rise in [Ca2+]i is facilitated by voltage operated calcium (VOC) channels as well as  non-
specific cation channels, most of which are known as transient receptor potential canonical 
(TRPC) channels (154). TRPC channels can either be activated by ligand binding to the cell-
receptor (as described previously) or by the depletion of internal Ca2+ stores, referred to as 
capacitative Ca2+ entry (155). VOC’s commonly found in the cerebral arteries are L-type 
(Cav1.2) and T-type (Cav3.1 and Cav3.2) Ca2+ channels (156). Of particular importance, VOC 
and TRPC channels do not remain static within the plasma membrane. Rather, expression at the 
cell surface is highly dependent on other intracellular molecules that they associate with, which 
influences their trafficking and activity in signal transduction processes (154) (Figure 2.3). 
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Figure 2.3: Schematic Diagram of Vascular Smooth Muscle Contraction. Activation of G-protein 
coupled receptor on the cell surface occurs when agonist binds to the receptor. This leads to the 
activation of PLC which catalyzes the cleavage of PIP2 into IP3 and DAG. IP3 triggers 
intracellular calcium release from the SR. DAG activates PKC which also increases intracellular 
calcium release through the opening of VOC’s and TRPC channels. An increase in intracellular 
Ca2+ concentrations allows Ca2+-CaM binding which activates MLCK, leading to the 
phosphorylation of MLC and subsequent muscle contraction.  
VOC – Voltage-gated Ca2+ Channel, TRPC – Transient Receptor Potential Canonical Channel, 
SR – Sarcoplasmic Reticulum, PLC – Phospolipase C, PIP2 - phosphatidylinositol 4,5-
bisphosphate, IP3 - inositol trisphosphate, DAG – diacyl glycerol, PKC – protein kinase C, CaM 
– Calmodulin, MLC – myosin light chain  
Adapted from Webb (2003) 
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2.4.3: Cerebral Blood Flow Autoregulation 
The concept of autoregulation was first described by Bayliss in 1902, by demonstrating 
that vascular tone could in part be modulated by intravascular pressure, through his experiments 
measuring blood flow in a canine hind limb (157). Currently, the four main regulators of cerebral 
blood flow have been determined to be 1) partial pressure of CO2 (PaCO2),  2) mean arterial 
pressure, 3) metabolic needs of the brain and 4) the autonomic nervous system (158). In 1959, 
Lassen modeled the data from seven separate studies recording the relationship between arterial 
blood pressures and corresponding cerebral blood flow using a curve, showing that cerebral 
blood flow was largely unchanged over a blood pressure range of approximately 60 mmHg-150 
mmHg. He termed this static autoregulation (159). As of late, this concept has been criticized 
and revised based on studies using the Windkessel model.  The Windkessel model is a 
mathematical model that describes hemodynamics in terms of vascular resistance, compliance 
and impedance (160). Evidence in the literature suggests that due to the compliance of cerebral 
arteries, it is possible that they are buffering against changes in blood pressure by “storing” blood 
throughout a cardiac cycle. This process would be dependent on how quickly blood pressure was 
changing (161, 162).  Conversely, in times of hypotension, cerebral blood flow was less 
effectively maintained than during acute hypertensive episodes (163, 164). At present, the 
concept of dynamic cerebral autoregulation and the active modulation of cerebral blood flow 
during perpetual changes in blood pressure (165, 166) is widely accepted. Although many 
believe that dynamic cerebral autoregulation is achieved primarily by a constant adjustment of 
arterial resistance within the cerebrovasculature (based on myogenic responses to stretch/stress 
as described previously) to arterial blood pressure, the precise mechanism by which this occurs 
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remains not fully defined (166). However, one important component of dynamic cerebral blood 
flow autoregulation is pressure dependent constriction (PDC).    
2.4.4: Pressure Dependent Constriction 
PDC describes the reflexive decrease in lumen diameter of an autoregulatory vessel (such 
as certain cerebral arteries) in response to an abrupt increase in blood pressure that would 
otherwise increase blood flow to the brain. This mechanism is believed to be protective during 
acute hypertensive episodes because when the perfusion pressure rises excessively, the blood 
vessel constricts, increasing vascular resistance and maintaining constant blood flow to the rest 
of the brain (24, 167). Studies of the pathogenesis of hemorrhagic stroke in the stroke prone 
spontaneously hypertensive rat revealed that before cerebral hemorrhage occurs, PDC is lost in 
the MCA (167) which corresponds to a loss in cerebral blood flow autoregulation to the areas 
downstream (168). Therefore, in times of acute hypertension, this alteration in vascular function 
is thought to lead to over-perfusion of vasculature downstream from the MCA, facilitating 
disruption of the blood-brain barrier and eventually ending in cerebral hemorrhage. Likewise, in 
chronic hypertensive vascular disease, weakened vessels would be much more prone to rupture 
in the presence of an acute spike in blood pressure from baseline (169). 
Just as the process of dynamic autoregulation of cerebral blood flow is not fully 
understood, neither is the process by which the MCA loses its ability to perform PDC. However, 
PDC is known to be dependent on endothelial function (170) as well as vascular smooth muscle 
function (171, 172). In SHRsp’s who are unable to perform PDC (post-stroke), the vasodilatory 
response to bradykinin is lost as well as the vasoconstrictor response to NOS inhibition (L-
NAME), indicating endothelial dysfunction (168). Additionally, various vascular smooth muscle 
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agonists (that increase [Ca2+]i by initiating Ca2+ release from the sarcoplasmic reticulum (173) 
and opening of receptor-operated Ca2+ channels in the sarcolemma (174)) including serotonin 
and vasopressin had reduced vasoconstrictor activity in post-stroke SHRsp but were rendered 
completely ineffective in the presence of L-type Ca2+ channel blockade. This suggested a defect 
in the ability of the vessel to use intracellular Ca2+ stores (172). Finally, a significant correlation 
between PDC and vascular response to PKC activation by phorbol dibutyrate (which directly 
activates PKC and also increases the sensitivity of the contractile pathway to available Ca2+ 
(175)) in the MCA of pre/post-stroke SHRsp was observed. After stroke development, SHRsp 
MCA’s had lost the ability to respond to PKC-mediated vasoconstriction, indicating a possible 
role for PKC activity in PDC (171). Therefore, deficits are apparent in various steps of the 
contractile pathway of the MCA, all of which are correlated to a concurrent loss in PDC and an 
increased risk of HS.       
2.5: Hemorrhagic Stroke 
Stroke remains a significant cause of death worldwide, causing approximately 5.5 million 
deaths annually (176). According to a recent report from the Heart and Stroke Foundation, the 
death rate arising from stroke in Canada is 17.9 per 100,000 people (29.9 in Newfoundland and 
Labrador) with one stroke occurring every 10 minutes (177). Although the most common stroke 
subtype is ischemic stroke (87%), between 10% and 15% of all strokes are of the intracerebral 
hemorrhage (ICH) subtype (178, 179), which is caused by the bursting of small cerebral 
arterioles. In the majority of cases, the trigger for vascular wall rupture is longstanding 
hypertension (180). Depending on the underlying cause, cerebral hemorrhage is further sub-
classified as primary ICH or secondary ICH. Primary ICH (78%-88% of cases) occurs when 
chronic vascular damage from longstanding hypertension and/or amyloid angiopathy weakens 
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the small arteries and arterioles in the brain making them susceptible to rupture leading to 
hemorrhage (181, 182). Alternatively, secondary ICH occurs in patients with underlying vascular 
anomalies (such as aneurysms), neoplasm or coagulopathies which make them prone to cerebral 
hemorrhage development (183, 184).   
2.5.1: Clinical Definition and Prevalence 
Hemorrhagic stroke (HS) is defined as an abrupt disruption in brain function caused by 
small cerebral vessel burst followed by bleeding into the cerebral parenchyma (178). Worldwide 
incidence ranges from 10-20 cases per 100,000 people, and increased risk with advancing age 
(185). Men are more commonly affected than women, especially after 55 years of age. 
Individuals of African and Japanese descent (50-55 cases per 100,000) have more than twice the 
risk of developing ICH than Caucasians (186-188). A higher fatality rate is observed in HS 
compared to the other subtypes of stroke, with 62% of patients dying within the first year post-
stroke and high risk of recurrence (189, 190).  HS can also be precipitated iatrogenically by 
treatment with first-line thrombolytic treatments used to dissolve clots in the treatment of 
myocardial infarction and ischemic stroke (191).  
2.5.2: Pathophysiology and Risk Factors 
As previously mentioned, chronic hypertension is the most significant risk factor for ICH 
development (192). A randomized, double-blind, placebo-controlled trial in elderly patients with 
systolic blood pressures ≥ 160 mmHg using anti-hypertensive medication had a five-year 
incidence rate of ICH of 5.2% compared to the placebo group who had a rate of 8.2% (193). 
Therefore, appropriate anti-hypertensive treatment in affected individuals is an important 
intervention in risk management (194, 195). Other modifiable risk factors include high salt 
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intake (196), excessive alcohol consumption and dyslipidemia (especially in the presence of 
hypertension) (197). Other non-modifiable risk factors for primary ICH include certain 
coagulopathies due to genetic mutations (198) and cerebral amyloid angiopathy, characterized by 
deposition of β-amyloid protein into the walls of cerebral vessels, compromising structure and 
function (182, 199).  
The changes in vascular structure and reactivity immediately prior to stroke in humans 
are not well elucidated at this time. However, HS development is thought to be precipitated by 
chronic hypertensive vascular remodeling, reflected by a decrease in the arterial elastic 
component and the partial replacement of vascular smooth muscle in the tunica media with 
collagen deposition (200). Because the elastic component of the vessel provides strength, 
increased collagen ratio renders the wall much more brittle and prone to burst under conditions 
of stress (200). In addition, Charcot and Bouchard identified isolated areas of cerebral arterioles 
that were dilated and identified these highly collagenized sites as the most likely points of 
rupture within the vascular wall. They are now termed Charchot-Bouchard aneurysms and are 
thought to play a role in cerebral micro-hemorrhage development that precedes gros cerebral 
hemorrhage resulting in clinical symptoms (178, 200-203). Therefore, due to these structural 
changes, the cerebrovasculature becomes prone to distension and vulnerable to over-perfusion. 
As previously described, amyloid angiopathy is also an important contributor to HS, particularly 
in the elderly. However, these areas of hemorrhage are usually characterized as being located 
more superficially on the surface of the brain as opposed to hypertensive-induced hemorrhages 
which tend to appear close to the Circle of Willis. Hypothetically, this is where the greatest 
amount of hypertension-induced vascular damage would occur due to the high pressures and 
frequent arterial bifurcations, contributing to turbulent blood flow (200).  
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Finally, the development of satellite lesions further worsens the disease progression. 
After the initial cerebral hemorrhage, the body increases production of catacholamines which 
further increases the blood pressure. Because vascular damage caused by chronic hypertension as 
well as amyloid angiopathy (when applicable) is widespread and not isolated to a single area, 
blood flow autoregulatory function is already presumably compromised globally. In the setting 
of autoregulatory dysfunction and leaking vessels, it has been shown that blood pressures of 150-
160 mmHg are key for the promotion of hematoma expansion. Therefore at high pressures, 
cerebral blood flow is more likely to increase, leaving the patient vulnerable to primary 
hematoma expansion but also the development of satellite hemorrhages (lesions), further 
exacerbating bleeding (200, 204, 205). This helps to explain the high case fatality rate in ICH 
patients. However, more information is needed regarding the molecular mechanisms of 
autoregulatory failure that plays a role in HS pathology. 
2.5.3: Animal Models of Hypertension and Stroke 
To date, no effective pharmacological agents have been developed to treat spontaneous 
ICH. This means stroke prevention is paramount, as supportive care is the only treatment 
modality initiated post-stroke. As a result, animal models to study ICH are crucial in increasing 
our understanding of the underlying pathology leading to stroke development as well as the 
exploration/development of experimental treatment options to improve survival outcomes in this 
population. The most commonly used genetically hypertensive animal model used in the study of 
essential hypertension is the stroke-resistant Spontaneously Hypertensive Rat (SHR). 
Alternatively, an appropriate animal model to study the pathogenesis of HS is the stroke-prone 
Spontaneously Hypertensive Rat (SHRsp). 
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2.5.3.1: SHR 
The most widely used genetically hypertensive rat model, the SHR, was developed by 
Okamoto and Aoki from selective breeding of a spontaneously hypertensive outbred male Wistar 
Kyoto (WKY) Rat with a slightly hypertensive female. Subsequent inbreeding of sibling pairs 
lead to the development of the SHR strain (206). Possibly attributable to the increased activity 
through the renin-angiotensin-aldosterone system, spontaneous hypertension develops at around 
five weeks of age, yielding systolic blood pressures as high as 200 mmHg by seven to ten weeks 
of age (207). Compared to normotensive WKY controls, SHR show signs of alterations in 
cerebral autoregulation linked to increased stiffness in large arteries and increased distensibility 
of small arterioles (208-210); however regardless of hypertension-related changes to the 
vasculature, SHR are highly stroke resistant. Due to this and the common genetic lineage, the 
SHR is commonly used as a stroke-resistant control for the SHRsp.  
2.5.3.2: SHRsp 
Originally developed by Okamoto et al, the inbred SHRsp model is an appropriate animal 
model to study HS-associated pathology as well as novel treatment strategies post-stroke (211). 
There are a number of strengths to using this model to study hemorrhagic stroke which include 
the similarity in mechanism and pathology of stroke development to humans and role of genetics 
in stroke occurrence. The SHRsp strain reliably produce hemorrhagic stroke at a rate of 88-100% 
by 10-13 weeks of age subsequent to longstanding hypertension when placed on a Japanese style 
high salt diet (HSD) from five weeks of age (212, 213). This relates well to human disease as 
chronic hypertension and associated vascular pathology is one of the key contributors to ICH. In 
our model, we used a 4% NaCl, 0.75% K+ HSD which typically produces 100% mortality by 
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around 15 weeks of age (213, 214). In addition, common areas of ICH due to hypertensive 
vascular disease in humans tends to be near areas of arterial bifurcations (202) which is also 
consistent in the SHRsp model. Yamori et al described the most common areas of cerebral lesion 
formation in the SHRsp to be the anteromedial cortex, the occipital cortex, and the basal ganglia 
(215) which share the common physiologic feature of frequent arterial branching. In addition, the 
frequency of “boundary zone” lesions, located at the areas of the brain supplied by both the 
posterior and middle cerebral arteries is also consistent with human disease (215).  Finally, the 
genetic predisposition to stroke development in the SHRsp compared to the SHRsr further 
reinforces the importance of genetics in HS development, a phenomenon also observed in 
humans. Although both strains exhibit similar levels of hypertension while consuming HSD, 
only the SHRsp develops predictable HS (207).  
The physiological mechanisms leading to HS development in the SHRsp to HS are multi-
factorial and include severe hypertension, vascular dysfunction leading to loss of autoregulation 
of cerebral blood flow, and weakening of the blood brain barrier (BBB) leading to cerebral 
hemorrhage formation (216). Due to the abnormally heightened activation of the renin-
angiotensin-aldosterone system in SHRsp, blood pressures in these rats often rise well over 200 
mmHg (216) along with cerebral lesion formation in downstream arterioles. A progressive 
increase in blood pressure leads to dysfunction of the BBB causing leakiness and subsequent 
extravasation of plasma proteins. Hypertensive vascular remodeling, as described previously 
damages the endothelial and vascular smooth muscle cell layers. This leaves behind the basal 
membrane and causes collagen deposition into the vascular walls, producing arteriolar necrosis 
(217). Subsequent cerebrovascular dysfunction accompanied by functional deficit in cerebral 
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blood flow autoregulation render the vessel vulnerable to ectasia and eventual rupture (18, 168, 
171, 218).   
2.6: Hypothesis 
 Currently, the main source of data that correlates increased HS risk and RA is population-
based epidemiological studies. As such, there is a large knowledge gap surrounding the 
pathogenesis and mechanism of this relationship. Based on the evidence available with the 
various autoimmune arthritis, hypertension and hemorrhagic stroke animal models, theories can 
be generated in an attempt to explain how chronic inflammation leads to cerebral hemorrhage. 
However, currently there is no multi-disease animal model that allows for the concurrent study of 
chronic hypertensive disease and chronic systemic inflammation to test these theories. As a 
result, there is also a lack in appropriate vascular studies in the setting of chronic hypertension 
and systemic inflammation to test functional aspects of the cerebral vessels.       
Our hypothesis is that chronic inflammation in the setting of longstanding hypertension in an 
ageing, stroke-resistant spontaneously hypertensive rat (SHR) predisposes the middle cerebral 
artery (MCA) to lose the ability to respond properly to pressure, leading to increased incidence 
of HS. In addition, we hypothesize that high salt diet in conjunction with chronic inflammation 
will further exacerbate dysfunction  in the MCA of inflamed, hypertensive SHR.  
 To address our research question, we developed the following study objectives: 
1) Create and define the relevant animal model to study the effect of arthritic inflammatory 
injury and hypertension on cerebral vessel function 
2) Investigate whether intracerebral hemorrhage occurs in this mono-arthritic, hypertensive 
animal model 
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3) Investigate the role of HSD on cerebral vascular function in this mono-arthritic, 
hypertensive animal model. 
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3.0: Materials and Methods 
3.1: Animals 
All experimental procedures and animal breeding was carried out at Memorial University of 
Newfoundland Health Sciences CentreAnimal Care Facility and were in compliance with 
guidelines and recommendations set forth by the Institutional Animal Care ethics committee and 
the Canadian Council on Animal Care (Guide to Care and Use of Experimental Animals, vol.1, 
2nd ed.). In total, 45 male stroke resistant Spontaneously Hypertensive Rats (SHR; Original stock 
from Charles River Laboratories, Quebec, Canada) were included in the study. The animals were 
bred in-house and were housed two per cage in ventilated cages under standard light cycle (12 
hour light/dark), controlled temperature, and humidity conditions. Experimental design for 
inducing inflammation was implemented at 20-28 weeks of age. Ad libitum access to food and 
water was permitted.  
3.2: Experimental Design 
Rats were divided into four experimental groups based on diet and treatment, and followed the 
experimental timeline outlined in Figure 3.1. Briefly, SHR-high salt diet (HSD) groups were fed 
a Japanese-style high salt diet containing 4% NaCl (Zeigler Bros, Gardners, PA, USA) from 
weaning. SHR-regular diet (RD) groups were maintained on standard rat chow (Laboratory 
Rodent Diet 500I, Lab Diet, St. Louis, MO, USA; 0.58% NaCl). At 20-28 weeks of age, they 
were randomly divided into 4 groups based on treatment (Complete Freund’s Adjuvant (CFA) 
model of mono-arthritis or Saline (SAL) injected control) and diet (high salt (HSD), or standard 
rat chow(RD)), and labelled HSD-SAL (n=10), HSD-CFA (n=14); RD-SAL (n=11), RD-CFA 
(n=10) (Figure 3.1). 
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Figure 3.1: Animal experimental timeline. Four experimental groups were followed over the 
course of 21-23 days, SHR-HSD-SAL, SHR-HSD-CFA; SHR-RD-SAL, SHR-RD-CFA. SHR-
HSD groups were weaned and started on Japanese Style High Salt Diet (4% NaCl) while SHR-
RD groups were weaned and started on regular purina (0.58% NaCl equivalent) diet at 5 weeks 
of age. At 20 weeks of age (Experimental Day 0), all groups received an intradermal injection in 
the left hind paw. Inflamed groups (CFA) received 0.07mL of CFA for the induction of adjuvant 
arthritis (AA) while control groups (SAL) received the same quantity of sterile saline (0.9%) 
solution.  All groups were monitored for signs of inflammation and hypertension. Broken yellow 
line represents experimental timeline in days (Day 0-Day 21).   
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Figure 3.1: Animal Experimental Timeline 
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3.3: Preparation of Complete Freund’s Adjuvant 
A suspension of Mycobacterium butyricum ([10 mg/mL]) in Incomplete Freund’s Adjuvant 
(Sigma, USA; IFA) was prepared according to modified methods for induction of adjuvant 
induced arthritis (AIA), as commercial sources of CFA have not been found suitable for arthritis 
induction. In order to insure success of disease induction, heat-killed M.butyricum H37RA 
(Sigma, USA) were ground into smaller particles until fine, using an autoclaved, marble mortar 
and pestle in a sterile fume hood. IFA was added gradually and grinding continued until 
thoroughly mixed to make CFA.    
3.4: Induction of Adjuvant Induced Mono-arthritis (AIA) 
Experimental arthritis was induced by intradermal injection of CFA (0.07 mL of 700 µg 
M.butyricum) into the plantar surface of the left hind paw of SHRs at day 0 of the experimental 
procedure while the animals were under anesthesia (isofluorane 4% inhalation for induction and 
2-2.5% for maintenance). Controls were injected with an equi-volume of sterile 0.9% saline 
solution under anesthesia.  
3.5: Monitoring of Development and Progression of AIA 
Animals were assessed for signs of inflammation for 21 days until the end of the experimental 
period from injection day (day 0). Wellness monitoring of rats was conducted twice daily, in 
conjunction with staff from the animal care facility according to a standard checklist provided. 
Animals were inspected for signs of dehydration, facial grimace, self-grooming, presence or 
absence of vocalizations while handling and mobility and also monitored for ulceration 
development. When significant vocalization and/or poor mobility were observed, inflamed rats 
were given 0.03 mg/kg buprenorphine every 12 hours as required for pain management. The 
dose and the frequency of buprenorphine injections were determined from previous studies 
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which deemed that the dose would not interfere with the inflammatory process or vascular 
function (219-221). Caliper measurements were taken every second day to measure hock and 
paw widths of both hind paws. Water displacement of each hind paw was determined by dipping 
the ipsilateral paw of the experimental animal up to the ankle in a standard scintillation vial with 
water (at a consistent weight) in order to gauge swelling of the paw as a whole. The amount of 
water displaced by the paw was calculated. In addition, animal weights and arthritic index scores 
were assigned to each rat during monitoring to separately evaluate redness and erythema of the 
toes, paw, hock and knuckles of the hind paws and forepaws, when applicable. Each area was 
assigned a score from 0-4, 0 being normal and 4 being severely inflamed. Scores were also 
assigned for lesion development and rated similarly on a scale of 0-4.  
3.6: Blood Pressure Measurement 
Blood pressure was recorded by tail-cuff plethysmography (Model 59, IITC Inc., Woodland 
Hills, CA, USA) at baseline before CFA/Saline injection and weekly thereafter for the 21-24 day 
experimental period. Experimental time points for measurement of blood pressures were at 0 , 7, 
14, and 21 days following hind paw injection. Four sequential readings were taken at 4 seconds 
apart per rat at each time point and the mean (of the systolic blood pressure) was recorded. The 
percentage change from baseline of systolic blood pressure was calculated. 
3.7: Identification of Cerebral Hemorrhage 
Upon the day of sacrifice at day 21-24, a random sample from the experimental rats (n=5/group) 
were anaesthetized with intraperitoneal injection of 50/10 mg/kg of ketamine:xylazine. The hair 
around the abdomen and hind limbs were shaved and cleaned with alcohol and iodine and the rat 
placed on a warm board for surgical preparation. The femoral vein at the contralateral side was 
isolated, and a modified sylastic tube catheter inserted and tied with a 4.0 suture. A 30 mg/kg 
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bolus dose of Evans-blue dye (Sigma, USA) (15 mg/mL 0.9% saline) was then slowly injected 
over a 20 second period and allowed to circulate approximately 25-30 minutes. The rats then 
underwent exsanguination for isolation of their brain and kidneys for further analysis. Because 
Evans-blue dye binds to plasma albumin, areas of extravasation of Evans-blue dye were deemed 
indicative of intracerebral hemorrhage based on previously reported data (18, 222). This is 
because extravasation of dye indicates sufficient disruption of the blood-brain barrier to allow 
passage of plasma proteins such as albumin. Brains of experimental rats that did not receive 
Evans-blue dye injection were also investigated to determine level of perfusion, cerebral edema, 
hemisphere size/symmetry and septal deviation, all indications of brain damage and associated 
with hemorrhage. 
3.8: Sample Isolation, Tissue Processing and Histological Staining 
Necropsy was performed on experimental days 21-24 after deeply anesthetizing the animals with 
intraperitoneal injection of 50/10 mg/kg of ketamine:xylazine. The animals were subsequently 
exsanguinated by cardiac puncture, using an 18G needle and heparinized 10 mL syringe. Plasma 
was isolated as described below (See TNF-α Analysis). The tibiotarsal joint of the contralateral 
ankle was removed at the medial and lateral malleolus using a small pair of pruning shears. The 
digits were then removed, allowing for better penetration of fixative and subsequent decalcifying 
solution. The ankles were fixed in 10% neutral buffered formalin (Fisher) for 48-92 hours, and 
further placed into Ca Ex II solution (Fisher), a Fixative/Decalcifier solution of 10% 
formalin/formic acid solution for decalcification. Completely decalcified samples were 
embedded in paraffin, and 4 µm sections were cut and stained using hemotoxylin and eosin 
(H&E) by standard procedures for assessment of joint degradation, synovium hyperplasia, 
angiogenesis, and inflammatory infiltrates. 
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 The brain was removed and placed in oxygenated (95% O2, 5% CO2) ice-cooled (≈3°C) HEPES 
Bicarbonate Buffer (130 mM NaCl, 4.02 mM KCl, 1.22 mM MgSO4, 4.05 mM NaHCO3, 1.84 
mM CaCl2, 9.99 mM HEPES, 1.18 mM KH2PO4, 0.02 mM EDTA, 5.99 mM glucose) which was 
prepared in-house, adjusted to pH 7.4 and filtered. The right and left MCAs were isolated, 
starting at the point distal to where it crosses the rhinalis fissure and mounted on a pressure 
myograph, as described later. The rest of the brain and a kidney were stored in fixative (4% 
neutral buffered formalin) for later histological examination 
3.9: TNF-α Analysis 
Tail vein blood samples (0.3-0.5 mL/sampling) were collected using a 253/8 G needle and 
heparinized (1000 IU/mL) syringes under anesthesia (isofluorane 4% inhalation for induction 
and 2-2.5% for maintenance) at baseline and weekly thereafter (n=5/experimental group). The 
samples were kept on ice and centrifuged at 45,000 rpm for 10 minutes within 2 hrs of sampling 
using a cooling centrifuge (Thermo-Fisher, ON, Canada). The supernatant was collected and 
stored in a -80 °C deep freezer until analysis. Plasma samples were analyzed for TNF-α 
(standard range 15.6 pg/mL – 1000 pg/mL; sensitivity 2 pg/mL) within the experimental period 
to determine induction of systemic inflammation using a TNF-α ELISA kit purchased from 
Biolegend (San Diego, CA, USA) as per manufacturer instructions.   
 
3.10: Pressure Myograph Experiments 
Isolated MCAs were mounted onto the Single Vessel Chamber component of the Pressure Servo 
System (Living Systems Instrumentation, VT, USA) for pressure myograph studies. Vascular 
response was imaged using an inverted microscope and measured using a Video Dimension 
Analyzer (Living Systems Instrumentation, VT, USA). Mounted vessels were tied off creating a 
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blind sack and pressurized to 100 mmHg and equilibrated for 30-45 min in an oxygenated 
(95:5% O2:CO2), temperature controlled (37 °C) environment. Baumbach et al previously 
described a decrease in blood pressure (BP) of >50% between that measured in the femoral or 
carotid artery compared to that measured in the distal portions of the middle cerebral vessels 
(210, 223, 224). As a result, all of the pressure myograph experiments were conducted at a 
resting pressure of 100 mmHg. We also conducted our myograph experiments in the MCA at 
resting pressure of 100 mmHg, as we believe the setting accurately models physiological mean 
BP in vivo in the MCA of the SHR, as arterial systolic BP ranges from 200 mmHg to 230 mmHg 
(225).  Pressure Dependent Constriction (PDC) was evaluated first. Following equilibration, the 
pressure was decreased to 0 mmHg for 6 minutes to disengage PDC (167). After this resting 
period, the pressure was immediately increased to 100 mmHg and lumen diameter was recorded 
(at the instant when the vessel experienced maximal pressure-mediated dilation; t=0) and then 
once more after 6 minutes. Previous work has shown that by 4-6 minutes PDC is re-engaged to 
control perfusion and maintain a constant lumen diameter in a healthy MCA (18). The effect of 
Bradykinin (1.6 μM) on the vessel was then tested by measuring the maximal vasodilatory 
response between 15 seconds and 1 minute. After the preparation was flushed with a sufficient 
amount of fresh HEPES bicarbonate buffer, the effect of NOS inhibition was then tested (L-
NAME (100 μM)). Lumen diameter was recorded at (immediately after the addition to L-
NAME) and then again at 5 minutes. A functioning endothelium should elicit a vasoconstrictory 
response. The contractile response of the vessel to intracellular Ca2+ release from the SR 
(vasopressin (1.23x10-7M)) and PKC activation (phorbol-dibutyrate (1 μM)) was then 
investigated from a maximally dilated state by blocking L-type Ca2+ channels with nifedipine (3 
μM). Prior to the addition of vasopressin, the percent reduction in lumen diameter from maximal 
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vasodilation with nifedipine was first determined (and up to 2 minutes). After washing the 
preparation, the vessel was maximally dilated with nifedipine as before and then incubated with 
phorbol-dibutyrate for 5 minutes.  
3.11: Evaluation of acute IL-17a exposure on MCA function (preliminary) 
One MCA was isolated from a sample (n=4-7/group) of each of the experimental animal groups 
and incubated with 100 ng/mL of rat IL-17A (Biolegend; San Diego, CA, USA) during the 
primary equilibration period for 45 minutes. Pressure myograph experiments were then 
conducted to measure PDC and the effects of vasoactive peptides as described in section 3.10.  
3.12: Statistical Analysis 
Statistical analysis was performed using SigmaPlot 12.5 (Systat Software Inc., San Jose, CA) 
and Excel 2010 (Microsoft Corporation, Redmond, WA). Data were analyzed using Analysis of 
variance (one-way and two-way ANOVA), with either Bonferroni, Tukey, Mann-Whitney Rank 
or Holm-Sidak post hoc analysis. Values of p<0.05 were considered statistically significant. 
Except where indicated otherwise, all data are expressed as mean± SEM. 
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4.0: Results 
4.1: Effect of diet and treatment on body weight 
Over the course of the experimental period, there was a statistically significant reduction in the 
weight from baseline (expressed as percent change in weight from baseline) in CFA compared to 
SAL treated animals regardless of the diet (Figure 4.1). Baseline weights of all animals were as 
follows; HSD-CFA: 339 ± 23.9 g, HSD-SAL: 342 ± 18.2 g, RD-CFA: 337± 22.0 g, RD-SAL: 
342± 18.2 g. There was no statistical difference between baseline weight measurements. The 
difference observed after the start of the treatment protocol is attributed to both the loss of weight 
in the CFA rats, particularly during the first week of treatment, and a steady increase in weight of 
the SAL rats over the 21 day period (Figure 4.1). 
4.2: Visual Determination of Mono-arthritis development 
CFA-injected animals developed mono-arthritis restricted to the joints of the injected ipsilateral 
paw within 2 days post-injection, and remained inflamed for the 21 days post-CFA injection 
(Figure 4.2 A-C). The degree of inflammation did not significantly differ between the HSD-CFA 
and the RD-CFA groups, and there were no signs of joint inflammation in the SAL-injected rats. 
Visual inspection of the CFA-injected animals revealed diffuse soft tissue swelling that included 
the digits. There was also visual evidence of joint damage with joint space narrowing of the 
intertarsal joints, and joint deformity by 21 days of CFA injection. In spite of the diffuse swelling 
covering the area from the toes up to the hock, many CFA-injected rats were still walking on the 
inflamed paw, with minimal evidence of pain. Some CFA animals showed minor inflammation 
at other sites including the contralateral, non-injected paw and/or one or both forepaws or the 
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tail, however this observation was not reliably seen at Day 21 and was commonly isolated to the 
early stages of inflammation (Days 1-7- Figure 4.3 ).  
Figure 4.1: Change in weight of the groups expressed as change in weight from baseline. Shown 
above is the averaged change from baseline in weight change with respect to time. Data was 
analysed by two-way ANOVA with Tukey’s post-hoc test . *p<0.05     
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Figure 4.1: Change in Weight of Regular and  
High Salt Diet Fed CFA and SAL Groups 
 
 
 
 
 
 
 
 
* 
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Figure 4.2: Representative images from all the experimental hind paws of Saline and CFA-
treated animals. From experimental day 2 to day 21, there was a statistically significant increase 
in ipsilateral paw circumference and volume in HSD-CFA (B) and RD-CFA (C) compared to 
SAL controls (A), as reflected in caliper and water displacement values. Representative images 
of the histological analysis of the paws upon H&E stains are also shown, at 4x and 20 x 
magnification. Both histological images are representations from the HSD experimental group. 
Histological analysis of the SAL-injected paws showed normal tissue, synovium, adipocytes, and 
collagen fibrils populating the joint area (D), with sharp transition between the intima and sub-
intima and characteristic morphological details associated with the layer, as seen in higher 
magnification (E).The sagittal section of CFA-injected paws demonstrates a denuded intimal 
layer and adipocytes (F), thickened and edemic sub-intima which have been largely replaced by 
inflammatory cell infiltrates, lymphocytes, and capillaries are congested and wall are thickened, 
evident in the 20x magnification (G).    
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Figure 4.3: Arthritic index scores for saline vs CFA throughout experimental timeline. Data was 
analyzed by two-way ANOVA using Holm-Sidak method with p<0.001 for CFA vs SAL in both 
groups only. 
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4.3 Histological Determination of Mono-arthritis 
H&E stains were performed on the sagittal sections of the ankles and qualitatively analyzed for 
cellular infiltration, joint degradation, and changes to the synovial lining (Figure 4.2 D-G). 
Sections obtained from saline-treated rats showed normal joint histology with a smooth articular 
surface and a regular tide mark separating the articular cartilage from the underlying subchondral 
bone (Figure 4.2 D, E). There was intact morphology of synovium and synovial lining, with no 
inflammatory cell infiltration, while CFA-injected rats showed a disrupted articular surface with 
total absence of cartilage in some areas. Both HSD (Figure 4.2 B) and RD (Figure 4.2 C) fed 
groups exhibited similar degree of inflammation, lesion formation, and the occasional lesions 
formation at the injection site upon visual inspection of the pad of the inflamed paw. Lesions 
also appeared at the hock as well, although never progressed to gross ulceration. There was 
minimal inflammation observed at the contralateral paws. There was no difference in the analysis 
of the HSD vs. the RD SAL-injected groups with regards to histological comparison. The sagittal 
section of CFA-injected paws demonstrates a denuded intimal layer and adipocytes (Figure 4.2 
F), thickened and edemic sub-intima which have been largely replaced by inflammatory cell 
infiltrates, lymphocytes, and capillaries are congested and walls are thickened, evident in the 20x 
magnification (Figure 4.2 G). There was also no difference in the qualitative analysis of the paw 
joint histology of the HSD vs. RD CFA-injected groups. 
4.4 Quantitative progression of mono-arthritis and inflammation 
The progression of inflammation from baseline to endpoint is shown in Figure 4.3. All rats were 
subjectively scored every second day based on level of redness/erythema as well as lesion 
formation in the toes, foot pad, knuckles and hock on both hind paws. An additional score was 
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given for redness/erythema or lesion formation in either of the forepaws. Each affected region 
was scored on a scale of 0-4, 0 being normal and 4 being the maximal severity. The maximum 
overall score was 20. Caliper measurements (Figure 4.4 A) of the cross-sectional width of the 
ipsilateral, injected hind paw and hock of the CFA treated animals remained significantly larger 
throughout the experimental timeline (p < 0.05) while no significant change was observed in the 
size of the left hind paw/hock of SAL-treated controls or in the contralateral hind paw/hock. 
Water displacement (Figure 4.4 B) of the paws was used to represent overall swelling of the 
affected foot, including the toes, knuckles, paw, and hock. Although there was no difference in 
paw volume of the contralateral hind paw for any group (p > 0.05), the volume of the ipsilateral 
hind paw remained significantly elevated in the CFA –treated cohorts (p <0 .05) while no change 
was observed in the SAL-treated animals. 
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Figure 4.4: Quantitative measurement of mono-arthritis using caliper measurements (A) and 
water displacement (B). Measurements are expressed as the average change in width of the left 
hock (A) or change in hind paw volume (B) compared to baseline with respect to time, measured 
every second day of the experiment. The mean of three measurements of each paw and hock 
were taken, while the volume displacement was measured only once.  Shown above is the 
change in width of the left hock compared to baseline measurements with respect to time. Data 
was analyzed using two-way ANOVA using Tukey’s post-hoc test.  *p<0.05    
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4.5 Systolic blood pressure 
Weekly blood pressure measurements were recorded from baseline (Day 0) to endpoint at day 
21, and the percent change from baseline was calculated and analyzed (Figure 4.5). The SHRs all 
remained hypertensive throughout the experimental period. The mean and standard deviation of 
the blood pressures at baseline within the groups was as follows; HSD CFA: 227.6 ±31.3 mmHg, 
HSD SAL: 246 ±23.3 mmHg, RD-CFA: 214±31.1 mmHg, RD-SAL: 224 ±15.4 mmHg. CFA-
treated animals had significantly higher blood pressure readings than SAL groups (p <0.05) at 
day 7. Day 21 readings also indicated significant differences in both diet and treatment induced 
percent change from baseline systolic blood pressures (HSD vs. RD p<0.05; CFA vs. SAL 
p<0.001). These results suggest that HSD and CFA effectively induce an increase in systolic 
blood pressure. 
4.6 Plasma TNF alpha levels 
Plasma samples from all treatment groups for Days 0, 7, 14 and 21 were analyzed for levels of 
TNF-α using a commercially available ELISA kit. The levels of TNF-α remained low at baseline 
(Day 0) for all treatment groups. Day 7 and 14 yielded statistically significant increase in TNF-α 
levels in HSD-CFA vs. HSD-SAL and RD-SAL groups. There was no significant difference in 
the HSD-CFA group compared to the saline controls at day 21 despite an evident numerical 
increase in TNF-α levels, due to the great variability in samples.  TNF-α levels of RD-CFA 
groups were statistically different only from HSD-SAL group in day 7 and 14. There was no 
statistical difference in TNF-α levels between the CFA treatment groups, suggesting that HSD 
does not affect the progression of arthritis development.  
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Figure 4.5: Percent change from baseline of systolic blood pressures of SHR-SAL vs. SHR-
CFAs on either HSD or RD. Four sequential readings were taken at four seconds apart per rat. 
The SAL and CFA groups were severely hypertensive throughout the experimental timeline at 
blood pressures above 180 mmHg. The percent change from baseline of the mean values of the 
systolic blood pressures are depicted (n=8-16/group). Data was analyzed using two-way 
ANOVA using Holm-Sidak post-hoc test.  * p<0.05, **p<0.001  
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Figure 4.6: Plasma concentration of TNF-α (pg/mL) per experimental group during the 
experimental period. Plasma samples were taken on day 0, 7, 14 and 21 of experimental period. 
ELISA analysis of samples was completed for n=5 from each experimental group. The average 
of the peak TNF-α plasma concentration for all rats in each group was calculated. Data was 
analyzed using one-way ANOVA using Tukey’s t-test for differences in mean values among 
groups (n=5-8/group). *p<0.05 
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Figure 4.6: Average Plasma Concentrations of TNF-α
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4.7 Determination of Cerebral Hemorrhage 
Experimental animals (n=3-8/group) were randomly selected for Evans-blue dye (EBD) injection 
at the time of sacrifice in order to identify areas of potential hemorrhage as evidenced by EBD 
extravasation. Figure 4.7 shows representative images of brains from SHR-SAL (Figure 4.7A) 
groups compared to CFA-treated animals on HSD (Figure 4.7B) and RD (Figure 4.7C) infused 
with EBD. Diet had no discriminable effect on SAL treated groups with regards to gross brain 
morphology. The brains appeared well perfused, with equi-sized hemispheres, a straight and 
healthy septum, with no evidence of EBD extravasation. EBD extravasation was more evident in 
all of the HSD-CFA brains (n=8), in forms diffuse and pin point, likely due to larger areas of 
hemorrhage. Most of the brains from RD-CFA groups (5 out of the 6 experimental animals 
infused with EBD) exhibited extravasation, as the presence of pin-point hemorrhages (PP). Signs 
of edema, and decreased cerebral perfusion, and distorted septum were especially apparent in the 
brains from CFA treated rats, with particularly higher incidence in the HSD-CFA treatment 
groups. Their brain morphology is akin to the stroke prone spontaneously hypertensive rats 
(SHRsp) who had developed hemorrhagic stroke, whose brains are characterized by a 
dysmorphic brain structure and deviated septum due to severe cerebral edema and fluid-filled 
lesions (169). There was also obvious asymmetry of both left and right hemispheres of the CFA 
rats compared to controls. 
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Figure 4.7: Evans-blue dye Infusion. Animals were anaesthetized and Evans Blue Dye was 
infused over a period of 25-30 minutes at the time of sacrifice. No signs of hemorrhage were 
apparent in controls (A), while CFA injected animals (HSD: B; RD: C) showed obvious signs of 
cerebral hemorrhage (circled). Pinpoint hemorrhage (PP); Cerebral hemorrhage (CH) 
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Figure 4.7: Evans-blue dye Infusion. 
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4.8 Effects of Diet and Inflammation on Vascular Function in the MCA 
4.8.1 Pressure Dependent Constriction 
All animals, regardless of diet or treatment, were able to constrict to a degree in response to 
increased intraluminal pressure, although there were significant variations between the groups 
with regards to the extent of the PDC response (Figure 4.8). We observed that both diet and CFA 
treatment affected PDC response. CFA treatment significantly diminished the ability of MCAs to 
undergo PDC in the RD group compared to SAL controls. However, there was no significant 
difference in the PDC response of the MCAs in HSD CFA compared to HSD SAL, which was 
attributable to the effect of the high salt diet on PDC. HSD alone had greatly diminished the PDC 
response in the vessel, as further evidenced by a significant decrease in PDC response in the 
HSD SAL group compared to the RD SAL group (p=0.01). 
4.8.2 Endothelium-Mediated Vasodilation: Bradykinin Response  
Figure 4.9 depicts the endothelial vasodilatory response of MCA’s to addition of bradykinin (1.6 
μM) (170, 218). The effect of inflammation (induced via CFA; treatment effect) was not evident 
within MCAs of RD groups (RD CFA vs. RD SAL). However, a significantly diminished 
response was observed in the MCA’s from HSD-fed CFA rats compared to HSD SAL rats 
(p=0.015). There was no difference in vessel response to bradykinin due to the effect of high salt 
diet (ie. RD SAL vs. HSD SAL). However, comparison between inflamed groups of the different 
diets indicated a significant decrease in relaxation in the HSD CFA cohort compared to the RD 
CFA (p=0.006), demonstrating the effect of both high salt diet and inflammation on bradykinin 
response in the MCAs. 
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4.8.3 NOS Inhibition: L-NAME Response 
Endothelial-mediated relaxation by nitric oxide (NO) was tested by the addition of a non-specific 
nitric oxide synthase (NOS) inhibitor L-NAME (100 μM), eliminating NO-mediated 
vasodilation. Induction of inflammation via CFA treatment did not significantly decrease 
response to L-NAME in the RD groups despite a trend in depressed response (RD CFA vs. RD 
SAL). However, there was a statistically significant decrease observed with CFA treatment in the 
HSD groups (HSD CFA vs HSD SAL; p=0.018) (Figure 4.10). No statistically significant 
difference was noted in MCA response to L-NAME between diets. As such, the combination of 
HSD and CFA treatments appears to be detrimental to the NOS system.  
4.8.4 Intracellular Ca2+ Release: Vasopressin Response 
The contractile response of the MCA to intracellular Ca2+ release by vasopressin (1.23x10-7M) 
was evaluated in the presence of nifedipine (L-type calcium channel blocker; 3 μM). There was 
no significant difference in the treatments in the RD group in their response to sarcoplasmic 
calcium release (RD CFA vs. RD SAL). However, a statistically significant difference was 
observed in the HSD rats between inflamed and non-inflamed rats, as the MCAs of  HSD CFA 
group had a significant diminished response to vasopressin compared to the HSD SAL group 
(p=0.03) (Figure 4.11). There was no difference in vessel contraction in response to vasopressin 
between diets (RD SAL vs. HSD SAL). This indicates that in the presence of a HSD, CFA 
treatment may interfere with intracellular Ca2+ release. 
4.8.5 PKC Activation – Phorbol Dibutyrate 
Phorbol Dibutyrate (1μM) was added to the MCAs to evaluate vascular smooth muscle response 
to PKC activation in the presence of nifedipine (3 μM) (Figure 4.12). A significant difference 
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was observed in the inflammation (CFA) groups compared to SAL of both RD and HSD groups. 
(p=0.047, RD CFA vs RD SAL;  p=0.018, HSD CFA vs. HSD SAL). There was no statistical 
difference in PKC activation between the diets (RD SAL vs. HSD SAL). This suggests that CFA 
treatment may interfere with PKC activation within the MCA, regardless of diet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
 
 
Figure 4.8: Pressure dependent constriction in regular and high salt diet fed CFA and SAL 
groups. Comparisons are made in the MCAs isolated from SHR HSD CFA (n=16), HSD SAL 
(n=13), RD CFA (n=12) and RD SAL (n=11) groups. Ability of the MCA to respond to a 100 
mmHg pressure step was evaluated as intraluminal pressure was raised from ~0 mmHg to 100 
mmHg. All values represent mean ± SEM. Data was analyzed using two-way ANOVA using the 
Holm-Sidak Method. * p<0.05 
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Figure 4.9: Bradykinin-induced relaxation in regular and high salt diet fed CFA and SAL-treated 
rats. Comparisons are made in the MCAs isolated from SHR HSD CDA (n=9), HSD SAL 
(n=11), RD CFA (n=10), and RD SAL (n=11) groups. Endothelial response was evaluated by 
adding 1.6 μM bradykinin to the buffer bath and measuring the % maximal dilation of the MCA 
(compared to dilatory response to 3 μM  nifedipine). All values represent mean ± SEM. Data was 
analyzed using two-way ANOVA using the Holm-Sidak Method. * p<0.05 
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Figure 4.10: L-NAME-mediated vasoconstriction in regular and high salt diet fed CFA and SAL-
treated rats. Comparisons are made in the MCAs isolated from SHR HSD CFA (n=16), HSD 
SAL (n=13), RD CFA (n=11), and RD SAL (n=11) groups. Endothelial response was evaluated 
by exposing the MCAs to 100 μM L-NAME and measuring the % decrease in luminal diameter. 
All values represent mean ± SEM. Data was analyzed using two-way ANOVA using the Holm-
Sidak Method. * p<0.05 
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Figure 4.11: Vasopressin-induced vasoconstriction in regular and high salt diet fed CFA and 
SAL-treated rats. Comparisons are made in the MCAs isolated from SHR HSD CFA (n=16), 
HSD SAL (n=13), RD CFA (n=12), and RD SAL (n=9) groups. Vascular smooth muscle 
response to intracellular calcium release was evaluated by exposing the MCA to 1.23x10-7M 
vasopressin and measuring the % decrease in luminal diameter from maximal dilation with 
nifedipine. All values represent mean ± SEM. Data was analyzed using two-way ANOVA using 
the Holm-Sidak Method. * p<0.05 
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Figure 4.12: Vasoconstriction to PKC activation in regular and high salt diet fed CFA and SAL-
treated rats. Comparisons are made in the MCAs isolated from SHR HSD CFA (n=16), HSD 
SAL (n=13), RD CFA (n=12), and RD SAL (n=9) groups. PKC activation in the vascular 
smooth muscle was evaluated by exposing the MCA to Phorbol-dibutyrate (1 μM) and 
measuring the % decrease in luminal diameter from maximal dilation with nifedipine. All values 
represent mean ± SEM. Data was analyzed using two-way ANOVA using the Holm-Sidak 
Method. * p<0.05. 
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4.9 The Effect of Diet and Acute IL-17a Incubation on Vascular Function in the MCA 
(preliminary study) 
To determine whether IL-17a is directly involved in vascular dysfunction induced by 
CFA treatment and/or HSD regimen, we incubated a sample of MCA’s with IL-17a prior to our 
pressure myograph experiements. IL-17a preincubation significantly decreased PDC (Figure 
4.13) and bradykinin-mediated vasodilation (Figure 4.14) in the RD fed animals, while no 
difference was observed with respect to responses to L-NAME (Figure 4.15), vasopressin 
(Figure 4.16) and phorbol-dibutyrate (Figure 4.18). In the HSD group, preincubation with IL-17a 
only affected the L-NAME response (with a significant decrease in constriction) while the 
MCA’s ability to undergo PDC, dilate to bradykinin and constrict in response to vasopressin and 
phorbol-dibutyrate were unaffected. This suggests that IL-17a may have direct effects on 
vascular function in the MCA. However, this effect differs based on the diet consumed by the 
animal. 
4.10 The Effect of Chronic Inflammation and Diet on MCA Response in the Presence of IL-17a 
A sample of MCA’s from RD CFA and HSD CFA groups were also incubated with IL-
17a and evaluated for changes in vascular function (data not shown). Incubation with IL-17a 
appeared not to alter any parameters of vascular endothelial or smooth muscle function in our 
MCA’s regardless of diet. However, our experiments were insufficiently powered to detect 
statistical differences due to small sample sizes (n=1-4 per group). Therefore the results are not 
yet interpretable. 
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Figure 4.13: Acute effects of IL-17a on pressure dependent constriction. PDC was measured in 
saline-treated SHR as described previously. Comparisons between RD Reg (n=11) vs RD +IL-
17a (n=4) and HSD Reg (n=13) vs HSD +IL-17a (n=7) were made. All values represent mean ± 
SEM. Data was analyzed using one-way ANOVA using Mann-Whitney Rank T-test. *p<0.05 
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Figure 4.14: Acute effects of IL-17a on bradykinin-mediated vasodilation. Bradykinin-mediated 
vasodilatory response was measured in saline-treated SHR as described previously. Comparisons 
between RD Reg (n=11) vs RD +IL-17a (n=4) and HSD Reg (n=11) vs HSD +IL-17a (n=6) were 
made. All values represent mean ± SEM. Data were analyzed using one-way ANOVA using 
Tukey’s T-test. *p<0.05 
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Figure 4.15: Acute effects of Il-17a on L-NAME-mediated vasoconstriction. MCA 
vasoconstriction to L-NAME was measured in saline-treated SHR as described previously. 
Comparisons between RD Reg (n=11) vs RD +IL-17a (n=4) and HSD Reg (n=13) vs HSD +IL-
17a (n=7) were made. All values represent mean ± SEM. Data was analyzed using one-way 
ANOVA using Tukey’s T-test. *p<0.05. 
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Figure 4.16: Acute effects of IL-17a on vasopressin-induced vasoconstriction. MCA 
vasoconstrictor response to intracellular calcium release (vasopressin) was measured in saline-
treated SHR as described previously. Comparisons between RD Reg (n=11) vs RD +IL-17a 
(n=4) and HSD Reg (n=13) vs HSD +IL-17a (n=7) are presented here. All values represent mean 
± SEM. Data was analyzed using one-way ANOVA using Tukey’s T-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
96 
 
 
 
 
 
 
 
 
 
 
97 
 
Figure 4.17: Acute effects of IL-17a on vasoconstrictory response to PKC activation. MCA 
vasoconstriction to activation of PKC (phorbol dibutyrate) was measured in saline-treated SHR 
as described previously. Comparisons between RD Reg (n=11) vs RD +IL-17a (n=4) and HSD 
Reg (n=13) vs HSD +IL-17a (n=7) are presented here. All values represent mean ± SEM. Data 
were analyzed using one-way ANOVA using Tukey’s T-test. 
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5.0 Discussion: 
Our model is unique in that it is the first animal model in which the induction of mono-
arthritis in a stroke-resistant hypertensive rat model potentiates the development of hemorrhagic 
stroke. This model incorporates the two important aspects in RA conditions which appear to 
predispose the patient to develop stroke: chronic high blood pressure and chronic inflammatory 
insult. This study also addresses the impact of high dietary salt content on increasing the 
systemic inflammatory response, and exacerbating the severity of the hemorrhage in our model.   
The CFA-induced mono-arthritis model exemplifies a moderate arthritic response while 
still inducing systemic inflammation compared to the tail-base, CFA-injected AIA model, which 
induces severe systemic inflammation, debilitating poly-arthritis, and chronic pain (64). While 
the latter model often raises concerns for animal welfare and comfort, the former model 
minimizes animal discomfort and allows for an arthritic injury to develop into polyarthritis as 
well as systemic inflammation. In our mono-arthritic hypertensive groups, the arthritic index of 
the forepaws and the contralateral paws rarely exceeded 0, indicating that although systemic 
inflammation was induced (as observed by increased plasma TNF-α levels), arthritis and joint 
degradation was likely isolated to the injected paw. Therefore, animals maintained full mobility 
of most of their limbs, and were able to reach the full 21 day period with minimal buprenorphine 
administration. The reduced severity of inflammatory response in the SHR strain is not 
associated with the site of the adjuvant injection (60). The SHR strain itself is deemed to be less 
prone to inflammation (226). The severity of the AIA model often prevents the experimental 
protocol from continuing to the full 21 day period and likely increases the need for higher doses 
(or frequency) of buprenorphine administration, a drug suggested to have variable effects on the 
vasculature in both chronic and acute administration settings (227, 228). 
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 The joint damage with our mono-arthritis model is reminiscent of the changes that occur 
with RA (17). There is defined degeneration of the joints and breakdown of cartilage, 
angiogenesis and vascularizations, and increased levels of cellular infiltrates in the synovium in 
the CFA-injected paw. The lack of distinction between the intimal and sub-intimal layers may be 
due to intimal thickening and/or a heavy immune cell infiltration in the subintima, both of which 
are characteristic of the structural changes to the synovium during progression of arthritis, in 
addition to synovial villus projections into the joint space (229, 230). These are all changes that 
are in part attributed to the action of TNF-α (231, 232). However, the systemic response is not as 
severe in the hypertensive SHR model, possibly due to this strain’s immunological resistance to 
the robust Th1 inflammatory response associated with the injection of CFA. This is due to the 
general suppression of cell-mediated immunity rendering them “immunologically depressed” 
compared to commonly used rat strains (226). Classic rat strains including Lewis rats, the Dark 
Agouti, and the Sprague Dawley rats (SDR) are genetically predisposed to mount a robust 
systemic inflammatory response to the mycobacterial component of CFA (233-235). Baseline 
TNF-α levels in the SDR model are approximately 3-fold higher than the SHR strain (data from 
BioLegend ELISA kit tests, unpublished) and induction of inflammation by CFA injection in the 
hind paw of the SDR along a similar timeline results in systemic TNF-α of 130-600 pg/ml in 
comparison to our mean peak levels of 66-200 pg/mL in SHR (236), (unpublished data from 
Fotso-Soh & Daneshtalab, 2015). While the increase in plasma TNF-α level in our hypertensive 
mono-arthritic rats are not as high as the SDR models, there is still an increase in the TNF-α in 
the CFA treated animals compared to the SAL counterparts. The increase in TNF-α level is slight 
in the RD CFA model, but it is still significantly higher (~3 fold) in the hypertensive-mono-
arthritic (HSD CFA) rats on the high salt (4% NaCl) diet (Figure 4.6).  
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In our model, gros cerebral hemorrhage was not present in the SAL groups, as the SHR 
strain is deemed to be stroke-resistant (207). It was only in conjunction with the mono-arthritic 
injury that evidence of gross hemorrhage and altered brain morphology occurred, regardless of 
the diet. Evidence shows that the loss of MCA’s ability to undergo PDC is linked to spontaneous 
hemorrhagic stroke development in the SHRsp model (169). The loss of MCA function is 
attributed to changes in endothelial or smooth muscle function in the SHRsp. If the MCA’s 
endothelial and vascular smooth muscle function were damaged, it would prevent the MCAs 
from undergoing PDC and properly auto-regulating the blood flow. It is possible that 
inflammatory mediators produced by our current mono-arthritic model, in conjunction with the 
underlying hypertensive physiology, played a role in the loss of MCA function by affecting 
various aspects of vessel function. Studies indicate that intracranial aneurysms are associated 
with physiological vascular remodeling that occurs in conjunction with inflammatory reactions, 
NOS dysfunction, and extracellular matrix remodeling (237-240). Moreover, there is a shift in 
the commonly accepted role of salt in potentiating cardiovascular diseases through traditional 
mechanisms such as hypertension and kidney dysfunction. More studies highlight salt’s integral 
role in impairing endothelial function, increasing arterial stiffness independent of blood pressure 
(241-243), and changes to the vascular endothelial glycocalyx layer and epithelial sodium 
channel to alter non-osmotic storage of salt (244). The increase in severity of HS and MCA 
dysfunction in the HSD CFA groups also suggests salt and inflammatory injury play a 
cooperative role in increasing cerebral vessel damage, in the presence of hypertension.  
The significant increase in TNF-α in our HSD CFA model (Figure 4.6) is reflective of the 
possible effect of salt in the diet potentiating the initial inflammatory injury by exponentially 
increasing the inflammatory response. Our results are consistent with ideas originally presented 
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by Kleinewietfeld et al and others in which sodium chloride drives autoimmune diseases (245-
248). Similarly, the activation of the Th17 pathway via sodium chloride was proposed to be 
involved in increasing the severity of the experimental autoimmune encephalomyelitis (EAE) in 
mice due to an increase in other pro-inflammatory cytokines such as TNF-α and IL-2. Our HSD 
CFA model shows similarities to the salt-EAE model previously proposed, as there is 
exacerbation of the inflammatory response and evidence of severe hemorrhagic stroke 
development as indicated by intracerebral extravasation of Evans-blue dye and visually apparent 
altered brain morphology with increasing cerebral edema, regional ischemia, decreased perfusion 
and deviation in hemisphere size. However, hemorrhagic stroke was also induced, albeit less 
severely as pin-point hemorrhages, in the RD CFA group who were fed a regular salt diet. 
Indeed, extravasation of Evans-blue dye was present in 100% of HSD-CFA and 84% of RD-
CFA groups investigated. Interestingly, the morphological appearance of the brains of the RD-
CFA animals appeared healthy, even with the pinpoint hemorrhages, particularly in comparison 
to what we have observed in post-stroke SHRsp models and our current HSD-CFA model. Also, 
as intracerebral hemorrhages do not always appear on the brain surface, the results of the RD-
CFA’s are not indicative of internal brain damage which requires further investigation. Although 
the TNF-α level was not statistically higher in the RD CFA compared to the SAL-treated 
animals, it was approximately 10-fold higher. Therefore, as an adjuvant arthritic model, this is 
reflective of the immune-complexity and heterogeneity that exists within the pathogenesis of 
RA, with high interpatient variability (249).  
A vast network of immune cells and cytokines are likely involved in the disease 
progression from the initial inflammatory injury, involving local recruitment and activation of 
immune cells as well as effector functions (250). The main pro-inflammatory cytokine directly 
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correlated with joint destruction in RA is TNF-α (251). In addition to its direct effects on joint 
degeneration, TNF-α induces several other pro-inflammatory cytokines such as interleukin-1 (IL-
1), interleukin-8 (IL-8), and granulocyte macrophage-colony stimulating factor (GM-CSF) (252). 
It mediates the expression, and in some cases amplifies the effects of, inflammatory mediators 
including IL-1β, PGE2, NO (253) and interleukin-6 (IL-6) in peripheral organs (254). 
Additionally, there is evidence of the involvement of TNF-α in increasing angiotensin II (AGII) 
levels and activity, and inducing nephron-glomerular damage, increasing urea and uric acid 
accumulation in plasma, inducing hypertension, and worsening endothelial dysfunction (255-
261). Periodic Acid-Schiff (PAS) staining of kidney samples from our animals (performed by 
Dr. Dickhout’s lab (unpublished)) revealed signs of inflammatory infiltrates and glomerular 
sclerosis in both inflamed groups (RD CFA and HSD CFA), although renal damage was more 
severe in the HSD  CFA rats with the appearance of obsolete (non-functional) glomeruli. 
Although saline-treated controls receiving HSD showed evidence of renal damage and immune 
cell infiltrates as well, the frequency of obsolete glomeruli and protein casts increased 
significantly after CFA treatment, as did the occurrence of inflammatory infiltrates. In contrast, 
the RD SAL cohort showed no signs of renal damage indicating that nephron-glomerular insult 
was attributed to high dietary salt content and/or inflammatory injury from CFA injection. As 
such, conditions associated with kidney damage precede the development of hemorrhagic stroke 
(262), and appears to be occurring in our hypertensive mono-arthritic model, although further 
investigation into the effect of kidney disease in our model is warranted. It is also likely that 
increases in various pro-inflammatory cytokines systemically induce central inflammation (in the 
brain) and cytokine production, promoting intracerebral damage directly and increasing 
104 
 
incidence of hemorrhagic damage in our hypertensive mono-arthritic models, and requires 
additional scrutiny.  
Intracerebral hemorrhages are also characterized by the middle cerebral artery (MCA)’s 
inability to undergo autoregulation and maintain constant cerebral perfusion, particularly during 
chronic hypertension. Our animal groups all remained hypertensive (at ~230mmHg compared to 
the normal blood pressure of less than 140 mmHg for a SDR strain) throughout the experimental 
period regardless of their treatment. Although there were no significant differences in blood 
pressure among the groups from baseline, there were variations throughout the experimental 
timeline associated with the diet or CFA-treatment (Figure 4.5). Regardless of this, the ability of 
the MCA to undergo PDC was significantly diminished in all groups relative to the RD SAL 
control (Figure 4.8). The maintenance of high systolic blood pressure is independent of diet 
among our experimental groups, which allows us to isolate the diet effect on MCA function as 
well, rather than blood pressure differences. Although Yamori et al found that with sustained 
levels of stress, spontaneous stroke can occur in up to 30% of SHRs (225), no signs of cerebral 
hemorrhage was observed in any of the SAL-treated SHR. 
Evidence in the literature indicates that MCA’s isolated from SHRsp prior to signs of 
stroke showed healthy responses to various vasoactive drugs which affect both endothelial and 
vascular smooth muscle function. Response to certain vasogenic peptides were all lost in the 
SHRsp after evidence of stroke, although response to phorbol dibutyrate was maintained to a 
lesser extent in some. Moreover, PDC was also lost, which indicates dysfunction in various 
aspects of vascular function as well (18, 168, 171, 218). Due to signs of gros cerebral 
hemorrhage found in both CFA groups in our study, comparisons between the various indicators 
of vascular function in our animal models and the pre-stroke and post-stroke SHRsp was 
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necessary. Our study showed the type of diet (HSD vs RD) and treatment (CFA vs SAL) affected 
different aspects of the MCA’s vascular function. When we compared treatment differences in 
our RD-fed rats’, vascular response to phorbol dibutyrate (Figure 4.12) and PDC (Figure 4.8) 
were significantly diminished with CFA compared to SAL but responses to bradykinin (Figure 
4.9), L-NAME (Figure 4.10) and vasopressin (Figure 4.11) were not affected. In our HSD-fed 
CFA rats, responses to all indicators of vascular function (bradykinin, L-NAME, vasopressin and 
phorbol dibutyrate) were significantly diminished with CFA treatment compared to SAL 
controls. However, there was no significant loss of PDC in the HSD rats between CFA and SAL 
treatment, which was unexpected. A comparison of the effect of diet (HSD or RD) on PDC 
showed a significant loss of PDC in the MCA with HSD compared to RD SAL animals, 
indicating that the diet alone may be causing vascular damage. Interestingly, although the HSD 
SAL rats had diminished response to PDC compared to their RD SAL controls, there were no 
signs of gross cerebral hemorrhage in the HSD-SAL group. This suggests that a diminished PDC 
response may not be sufficient to elicit vessel rupture or signs of gross hemorrhage on its own. 
However, chronic inflammation may be triggering a sequence of events within the MCA leading 
to changes in the autoregulatory capacity of the vessel, regardless of diet.   
The lack of appropriate autoregulatory function in the MCA of the HSD SAL rats is 
likely attributed to the effects of chronic high salt diet on the endothelium and its homeostatic 
functions. Endothelial dysfunction secondary to chronic salt intake has been linked to increased 
endothelial production of Transforming Growth Factor (TGF)-β which in turn increases the 
production of reactive oxygen species (ROS) through NADPH oxidase-4 (NOX4), leading to 
decreased NO bioavailability (263, 264). In male SDRs, aortic vascular endothelial 
[Ca2+]i signaling in response to histamine and methacholine was impaired after a short term 8% 
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NaCl diet (243). Although there was no significant decrease in the ability of the HSD SAL group 
to respond to bradykinin (Figure 4.9), endothelial dysfunction involving changes in ROS and 
endothelial Ca2+ regulation may occur as possible mechanisms of PDC failure. The lack of 
difference in PDC response between HSD-fed animals may therefore be accounted for by the 
significantly detrimental effects of the HSD to various aspects of MCA’s endothelial function 
involved in regulating PDC to a point where additional damage caused by inflammatory injury 
were likely negligible in the HSD CFA group. We can, however, observe the direct effect of 
inflammatory treatment on MCA function in our RD-fed groups, as evidenced by 
cerebrovascular function in the RD CFA group. 
The RD CFA group had significantly diminished PDC response, indicating that 
inflammatory pathology may be involved directly in autoregulatory dysfunction. One possible 
mechanism by which this altered vascular response may have occurred is by the increased 
expression of specific transient receptor potential (TRP) channels. Recent data is now showing 
an association between chronic inflammatory conditions such as RA and increased expression of 
TRP channels at the cell surface (265-267). TRP channel upregulation can be triggered by 
increased and persistent local production of ROS and pro-inflammatory cytokines, increased 
kinase activity such as NF-кB (268), and other physical and chemical cell-stress signals (267). 
Two types of channels that are known to be present in cerebral arteries are TRPV1 and TRPV4. 
When activated by increased [Ca2+]i in the endothelium, they cause vasodilation (148). It may be 
that over-expression of TRPV1 occurs in RD CFA due to the increased inflammatory milieu, 
which could explain why the pressure-induced contractile response was impaired while the 
bradykinin vasodilatory response remained intact.     
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The effect of inflammatory mediators on the endothelium has also been studied with the 
interaction between TNF-α and eNOS. Evidence shows that TNF-α interferes with endothelial 
nitric oxide (eNOS) production at the mRNA level by inhibiting the eNOS promoter and 
destabilizing the mRNA. This leads to endothelial dysfunction and vasoconstriction due to a 
shortage of eNOS (269). In our study, evaluation of the MCA’s response to bradykinin (which 
causes NO release in the vascular endothelium leading to vasodilation) and L-NAME (an 
inhibitor of NOS, which decreases NO release and leads to vasoconstriction) was performed. The 
HSD CFA exhibited a significant decrease in response to both bradykinin and L-NAME 
compared to HSD SAL, whereas no difference was observed between treatments in the RD-fed 
animals. It appears that endothelial dysfunction is exacerbated by chronic high salt diet and 
inflammatory insult, leading to the diminished response to bradykinin. Alternatively, bradykinin 
activates other vasodilatory effectors including endothelial derived hyperpolarizing factor 
(EDHF) (147). Kessler et al. showed that chronic elevation of pro-inflammatory cytokines such 
as IL-1β and TNF-α are known to decrease the production of EDHF, leading to diminished 
EDHF-initiated relaxation of the vascular smooth muscle (25). The degree of systemic 
inflammation, as observed by the plasma levels of TNF-α were approximately 8-fold higher in 
the HSD CFA group compared to HSD SAL and 3-fold higher than the RD CFA cohort (Figure 
4.6). It is possible that the magnitude of the TNF-α-incited EDHF and eNOS inhibitory effects 
may be occurring more prominently among HSD-fed, CFA-treated rats, lending evidence to 
possible interactions between HSD and inflammation to promote further endothelial damage. 
TNF-α levels were not statistically higher in the RD CFA rats compared to RD SAL rats, which 
may potentially explain why there was no significant difference in L-NAME or bradykinin 
response between inflamed and non-inflamed RD-fed SHR.   
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The evidence of the direct effects of HSD on endothelial response is well-established, as 
a wealth of literature exists to link dietary sodium chloride to endothelial dysfunction. Chronic 
high salt intake is correlated to decrease in NO bioavailability, and increased endothelial and 
arterial stiffness, diminishing vascular integrity and compliance (127, 241, 244, 270). Direct 
effects of the HSD on cerebral vessels may explain why our RD SAL group had a significantly 
better vasodilatory response to bradykinin than the HSD SAL group and why observed 
cerebrovascular damage (particularly on the endothelium) was exponentially increased when 
HSD was combined with inflammatory injury in the HSD CFA group (as seen in the diminished 
response to bradykinin).  
Our results indicate that there is also a significant degree of vascular smooth muscle 
dysfunction, which is associated primarily with CFA treatment rather than diet effect. However, 
there were differences in the degree of vascular smooth muscle damage associated with both diet 
and inflammation. While the HSD CFA group had a significantly diminished response to both 
vasopressin and phorbol ester (compared to HSD SAL), the RD-fed CFA group only showed a 
diminished response to PKC activation (compared to RD SAL). MCA remodeling due to an 
increase in inflammatory mediators may be accountable for the dysfunctional response to 
sarcoplasmic calcium release (vasopressin) as well as PKC activation (phorbol dibutyrate) (144, 
152, 171). TNF-α is a potent stimulator of vascular remodeling for the smooth muscle cell layer 
of the vascular wall, increasing matrix metalloproteinase activity and increasing proliferation of 
vascular smooth muscle cells (271, 272). The impaired response to PKC activation in both 
inflamed groups is akin to the decrease in PKC observed in the post-stroke SHRsp (171). 
However, the MCA’s of these post-stroke SHRsp were also unable to constrict in response to 
vasopressin as well, which was only apparent in our HSD-fed CFA group. Binding of 
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vasopressin to its receptor (V1) activates the vascular contractile response through activation of 
phospholipase C (PLC) which triggers a series of downstream events leading to release of Ca2+ 
from the sarcoplasmic reticulum, secondary to the cleavage of phosphatidylinositol 4,5-
bisphosphate (PIP2) and release of inositol trisphosphate (IP3) (273). However, this mechanism 
also releases diacylglycerol (DAG) which additionally translocates and activates PKC (273). In 
our model, inflammation and HSD may impair both the PLC/ IP3 along with the PKC system. 
The RD-fed CFA group on the other hand, only exhibited dysfunction in PKC activation while 
maintaining PLC/ IP3 signaling, which appears to occur in spite of the necessary cooperation of 
the pathways after V1 receptor activation. Interestingly, the RD-fed CFA groups still showed 
signs of pinpoint hemorrhages despite a functioning MCA. This indicates that although there are 
absolute signs of vascular dysfunction and stroke-related changes to cerebral vascular function, it 
is still possible to have hemorrhagic stroke without exhibiting all levels of dysfunction 
exemplified by the post-stroke SHRsp (ie: lack of response to bradykinin, L-NAME, 
vasopressin, phorbol dibutyrate and PDC).  
In conjunction with the effect of salt and inflammatory injury in promoting intracerebral 
hemorrhage, the age of the SHRs themselves is also important.  Preliminary studies in the SHR 
to induce HS with CFA injection failed if the animals were younger than 3 months of age. The 
optimal age for creating the hypertensive mono-arthritic model was 20-28 weeks of age (~5-7 
months), equivalent to approximately 20-40 human years (274). We believe the model at this age 
better reflects the onset and progression of RA; although RA can start at any age, it often peaks 
between ages of 30-50 years, regardless of genetic predisposition.  
Our results indicate that inflammatory injury in the setting of high dietary sodium intake 
and chronic hypertension leads to a more severe course of inflammatory autoimmune disease and 
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predisposes the patient to developing an apparently more severe form of hemorrhagic stroke. 
Based on the presence of inflammatory infiltrates in the kidneys of our HSD-fed, saline controls, 
it is likely that elevated dietary sodium alone is initiating a type of inflammatory process. In vitro 
and in vivo data shows that in the presence of a modest sodium increase, pathogenic Th17 
induction occurs, leading to tissue inflammation (275). Subsequent inflammatory insult by way 
of CFA injection inarguably exacerbates this process, leading to diffuse renal damage and also 
cerebral hemorrhage. The varying levels of hemorrhage observed in our model, being less severe 
than what is usually observed in the SHRsp model, allowed us to correlate the subsequent tiers of 
cerebrovascular dysfunction compared to the SHRsp model.  
5.1: Limitations and Future Directions 
Although our goal was to study the mechanism of hemorrhagic stroke in an animal model 
of RA and chronic hypertension, there are several limitations to our data. We did find signs of 
cerebral hemorrhage in our inflamed animals on Day 21 however, we do not currently know 
when stroke occurred, as we did not observe obvious acute signs of stroke (ie: hemi-paralysis, 
twitching, “slug” behavior associated with stroke occurrence in the SHRsp model), making it 
difficult to correlate the observed vascular dysfunction with our cytokine assay data. Although 
TNFα levels seemed to peak at Days 7 and 14 as well, we cannot correlate this to the timing of 
cerebral hemorrhage or link the acute peak to our vascular function analysis, as cytokine levels 
had dropped by Day 21 in the RD-fed animals. Although there may be acute vascular effects of 
these pro-inflammatory cytokines, our study was not appropriately designed to detect these 
effects. Sacrifice and sampling of our animals at multiple time points (Day 7, 14 and 21) would 
provide more information to correlate the vascular implications of acute spikes in inflammatory 
mediators, allowing us to more appropriately narrow down the time frame at which cerebral 
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hemorrhage is occurring. Additionally, extrapolation of our stroke pathogenesis results to the 
human RA population is not completely applicable at this time. While it is widely accepted that 
atherosclerosis is positively correlated to human stroke development, this factor is absent as our 
rat model does not develop atherosclerosis (276). Therefore, comparison made between our 
model of hemorrhagic stroke and human disease must be made with caution. Another potential 
limitation is the apparent decrease in blood pressure in all groups on Day 7 of our experimental 
timeline. Because animals were not previously acclimatized to being frequently handled or 
having their blood pressure measured, it is very likely that they were stressed on the day of their 
baseline reading. This possibly gave a false trend of blood pressure decreasing one week after 
injection. Therefore, acclimatization of rodents to the blood pressure monitoring protocol as well 
as regular handling for two weeks prior to the start of experiments would help to avoid 
misinterpretation of results. Conversely, the use of implantable telemeters would likely yield 
much more consistent blood pressure monitoring throughout the experimental period, 
eliminating handling bias.   
Evaluation of endothelial function only included analysis of vascular response to 
bradykinin and NOS inhibition, which does not provide a complete picture of endothelial 
function as a whole since mediators such as EDHF and PGI2 also play a role in endothelial-
mediated vasodilation. In addition, alterations to vascular response to NOS inhibition only 
generates partial insight into inflammation-related changes to the MCA. Data suggests that IL-17 
may have direct effects on the activity of eNOS (100), requiring appropriate characterization of 
active versus inactive eNOS expression in the MCA. We also believe that modulation in 
expression of certain TRP channels may be involved in changes to MCA function. Therefore, 
characterization of TRP channel expression (especially TRPV4) on the vascular endothelium 
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would test this hypothesis. It would also be interesting to test expression patterns of the various 
VOC and TRPC channels in the smooth muscle of the MCA as well.   
Of particular importance is the fact that our preliminary data evaluating vascular function 
in the presence of acute IL-17a exposure is insufficiently powered at this time to detect 
statistically significant differences in many of our groups. Therefore, these data are not 
interpretable at this time but rather represent an area for future work. This future work should 
also include characterization of TRPV4 channel expression pre-and post-incubation with IL-17a 
to further test our hypothesis that TRP channel expression is playing a role in functional 
alterations to the MCA. 
Conclusion 
Essentially, our results demonstrate that the combination of chronic inflammation and 
high dietary salt intake is detrimental to the mechanical functioning of the cerebrovasculature in 
the setting of chronic hypertension. This failure is evidenced by not only cerebral vascular 
dysfunction but ultimately the inability to effectively autoregulate lumen diameter of the MCA 
leading to over-perfusion and cerebral hemorrhage. 
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